



BRNO UNIVERSITY OF TECHNOLOGY

VYSOKÉ UČENÍ TECHNICKÉ V BRNĚ

FACULTY OF CHEMISTRY

FAKULTA CHEMICKÁ

INSTITUTE OF MATERIALS SCIENCE

ÚSTAV CHEMIE MATERIÁLŮ

THE EFFECT OF BIOLOGICALLY ACTIVE SUBSTANCES ON THE STRUCTURE AND PROPERTIES OF COLLAGENOUS SUBSTRATES

VLIV BIOLOGICKY AKTIVNÍCH LÁTEK NA STRUKTURU A VLASTNOSTI KOLAGENOVÝCH SUBSTRÁTŮ

MASTER'S THESIS

DIPLOMOVÁ PRÁCE

AUTHOR

AUTOR PRÁCE

Bc. Johana Babrnáková

SUPERVISOR

VEDOUCÍ PRÁCE

doc. Ing. Lucy Vojtová, Ph.D.

BRNO 2016



Vysoké učení technické v Brně
Fakulta chemická
Purkyňova 464/118, 61200 Brno

Zadání diplomové práce

Číslo diplomové práce:	FCH-DIP0914/2015	Akademický rok: 2015/2016
Ústav:	Ústav chemie materiálů	
Student(ka):	Bc. Johana Babrnáková	
Studijní program:	Chemie, technologie a vlastnosti materiálů (N2820)	
Studijní obor:	Chemie, technologie a vlastnosti materiálů (2808T016)	
Vedoucí práce	doc. Ing. Lucy Vojtová, Ph.D.	
Konzultanti:		

Název diplomové práce:

Vliv biologicky aktivních látek na strukturu a vlastnosti kolagenových substrátů

Zadání diplomové práce:

- 1) Literární rešerše na téma porézní kolagenové substráty pro buňky a léčiva aplikované v tkáňovém inženýrství
- 2) Příprava kolagenových substrátů s aditivy zvyšující jejich biologickou aktivitu
- 3) Chemicko-fyzikální charakterizace připravených vzorků
- 4) Biologická in-vitro charakterizace připravených substrátů
- 5) Porovnání výsledků, diskuze
- 6) Závěr

Termín odevzdání diplomové práce: 6.5.2016

Diplomová práce se odevzdává v děkanem stanoveném počtu exemplářů na sekretariát ústavu a v elektronické formě vedoucímu diplomové práce. Toto zadání je přílohou diplomové práce.

Bc. Johana Babrnáková
Student(ka)

doc. Ing. Lucy Vojtová, Ph.D.
Vedoucí práce

prof. RNDr. Josef Jančář, CSc.
Ředitel ústavu

V Brně, dne 31.1.2016

prof. Ing. Martin Weiter, Ph.D.
Děkan fakulty

ABSTRACT

The thesis deals with the preparation of 3D porous collagen scaffolds by freeze-drying and their modification with bioactive compounds. The natural polysaccharides, chitosan, calcium oxidized cellulose and chitin/chitosan-glucan complex for the modification have been used. The mechanical properties of the scaffolds have been enhanced by crosslinking process with carbodiimides. Growth factors have been delivered in the form of platelet lysate.

The influence of biologically active additives, crosslinking agents, and enrichment with growth factors on the properties of the prepared scaffold and their bioactivity in tissues of living organisms have been investigated. Specifically, this study includes the morphological properties, structure, porosity, swelling stability, chemical composition, temperature of denaturation and biological properties. Scanning electron microscopy, infrared spectroscopy, differential scanning calorimetry and confocal microscopy have been used to the characterization.

Prepared collagen substrates involving bioactive additive and platelet lysate could be used as scaffold for growing cells in systems with low mechanical loading and which has potential application in biomedicine.

ABSTRAKT

Diplomová práce se zabývá přípravou 3D porézních kolagenových skafoldů metodou lyofilizace a jejich modifikací bioaktivními látkami. K modifikaci byly použity přírodní polysacharidy – chitosan, vápenatá oxidovaná celulóza a chitin/chitosan-glukanový komplex. Mechanické vlastnosti skafoldů byly upraveny síťováním pomocí karbodiimidů. Růstové faktory byly dodány formou destičkového lyzátu.

Byl zkoumán vliv biologicky aktivních aditiv, síťovacího činidla a obohacení růstovými faktory na vlastnosti připravených skafoldů a jejich bioaktivitu v tkáních živých organismů. Konkrétně byly studovány morfologické vlastnosti, struktura, porozita, botnání, stabilita, chemické složení, teplota denaturace a biologické vlastnosti. K charakterizaci byly použity metody rastrovací elektronová mikroskopie, infračervená spektroskopie, diferenční kompenzační kalorimetrie a konfokální mikroskop.

Připravené kolagenové substráty obohacené bioaktivním aditivem a destičkovým lyzátem mohou být využity v biomedicině jako skafoldy pro růst buněk v systémech s nízkou mechanickou zátěží.

KEY WORDS

Tissue engineering, scaffold, collagen, freeze-drying.

KLÍČOVÁ SLOVA

Tkáňové inženýrství, skafold, kolagen, lyofilizace.

BABRNÁKOVÁ, J. *The effect of biologically active substances on the structure and properties of collagenous substrates*. Brno, 2016. 108 p. Diploma thesis, Brno university of Technology, Faculty of Chemistry, Institute of Materials Science. Supervisor doc. Ing. Lucy Vojtová, Ph.D.

DECLARATION

I declare that my diploma thesis was worked out independently and that the used references are quoted correctly and fully. The content of the above mentioned thesis is considered a property of BUT Faculty of Chemistry and can be used for commercial purposes only with the supervisor's and dean's consents.

.....
author's signature

PROHLÁŠENÍ

Prohlašuji, že jsem diplomovou práci vypracovala samostatně a že všechny použité literární zdroje jsem správně a úplně citovala. Tato práce je z hlediska obsahu majetkem Fakulty chemické VUT v Brně a může být využita ke komerčním účelům jen se souhlasem vedoucího diplomové práce a děkana FCH VUT.

.....
podpis diplomanta

Acknowledgments:

I would like to thank my supervisor Doc. Ing. Lucy Vojtová, Ph.D. for helpful discussions, interest and English correction, Ing. Veronika Švachová for valuable advices, the creation of good work conditions and everything, Dr. Abdel-Mohsan Abdel-Lattif, Ph.D. for preparation of chitin/chitosan-glucan complex, Ing. Jana Brtníková, Ph.D. for SEM images, Ing. Petr Sedláček, Ph.D. for DSC measurement, Ing. František Ondreáš for DMA testing and all colleagues involved in this work.

CONTENT

1	INTRODUCTION.....	7
2	CURRENT STATE OF THE ART	8
2.1	Regenerative Medicine	8
2.2	Tissue Engineering.....	8
2.3	Cells	9
2.4	Signals.....	10
2.4.1	Platelet-Rich Plasma.....	11
2.5	Scaffold	15
2.5.1	Properties of Scaffold Matrices	16
2.6	Biomaterials for Scaffolds	17
2.6.1	Natural Polymers	18
2.6.2	Synthetic Polymers	19
2.6.3	Bioceramics	20
2.6.4	Biocomposites	20
2.7	Collagen	20
2.7.1	Structure of Collagen.....	21
2.7.2	Physical and Chemical Propetries	23
2.7.3	Crosslinking.....	26
2.8	Scaffold Fabrication Techniques	29
2.8.1	Conventional Scaffold Fabrication Techniques	30
2.8.2	Solid Freeform Fabrication Techniques	31
2.8.3	Collagen Scaffold the Most Used Fabrication Techniques	32
2.9	Collagen-Based Scaffolds for Tissue Engineering and Their Application	35
2.9.1	Pure Collagen Scaffold	35
2.9.2	Collagen/Natural Polymer Blend Scaffold	35
2.9.3	Collagen/Synthetic Polymer Blend Scaffold	35
2.9.4	Collagen/Inorganic Hybrid Scaffold	36
2.9.5	Collagen Scaffold Modified with Growth Factors	36
2.9.6	Applications of Collagen-Based Scaffolds in Tissue Engineering.....	36
3	EXPERIMENTAL PART	39
3.1	Chemicals.....	39
3.2	Equipments	39
3.3	Preparation of Chitin/Chitosan-Glucan Complex	39
3.4	Preparation of Samples	39

3.4.1	Collagen Sponges	39
3.4.2	Collagen Sponges with CaOC	39
3.4.3	Collagen Sponges with Chitosan	39
3.4.4	Collagen Sponges with Complex	39
3.4.5	Crosslinking of Collagen Sponges with Carbodiimides.....	39
3.4.6	Sponges Enriched with PRP	39
3.5	Characterization of the samples	39
3.5.1	Morphology and Porosity	39
3.5.2	Swelling Ratio and Water Content	39
3.5.3	Degradation	39
3.5.4	Fourier Transformed-Infrared Spectroscopy	39
3.5.5	Differential Scanning Calorimetry	39
3.5.6	Biological Properties	39
4	RESULT AND DISCUSSION.....	40
4.1.1	Morphology and Porosity	40
4.1.2	Swelling Ratio and Water Content	40
4.1.3	Degradation	40
4.1.4	Fourier Transformed-Infrared Spectroscopy	40
4.1.5	Differential Scanning Calorimetry	40
4.1.6	Biological Properties	40
5	CONCLUSION	41
6	REFERENCES.....	42

1 INTRODUCTION

Collagen as a material for tissue engineering has long been studied for its unique biological and mechanical properties similar to the extracellular matrix. It is obtained from renewable sources which are physiologically intimate or almost identical to collagen in the human body. Creating a 3D porous structure, collagen may be used as a scaffold, which is able to substitute soft tissues. However, collagen has imperfections which can be eliminated by combination with other biomaterials. Many researches are aimed at modifying of collagen scaffolds using biodegradable polymers. Then the resulted scaffold exhibits suitable mechanical properties, stability and a certain biocompatibility required for regeneration of damaged tissue. The bioactivity is here the missing feature, which mediates the matrix interaction with live tissue and becomes indispensable component during regeneration of damaged tissues.

By collagen scaffold modification using biologically active substances, the scaffold is able to provide not only supportive environment for cell growth of new tissue, but also accelerate the growth. Activity means the inclusion of additive substances into the metabolic processes of cells. Substances which were chosen to modify collagen scaffolds are oxidized cellulose, chitosan, and chitin/chitosan-glucan complex. These are polysaccharides that are derived from natural sources, they are biodegradable and exhibit biological activity.

Complete tissue regeneration occurs as supplies of signals which initiate the healing process, the proliferation of cells and mediate communication between the scaffold and undamaged cells. Here it is necessary to use growth factors derived from autologous tissue, otherwise it may occur allergic reactions. An effective method has been proposed to use blood lysate due to high content of growth factors and ease of preparation.

By combining the collagen, bioactive agents and growth factors, a proper scaffold is prepared. It can replace the extracellular matrix and is a suitable environment for adhesion and proliferation of cells. The scaffold performs these functions for a period of recovery, which gradually degrades while forming new tissue structure.

Comparing the results obtained from the prepared scaffolds, the use of scaffolds for tissue engineering and further adjustment will be able to better specify.

2 CURRENT STATE OF THE ART

2.1 Regenerative Medicine

Regenerative medicine is a broad interdisciplinary field defined by the goal of reconstructing, repairing, or replacing missing or damaged tissue (cells, organs) to a state as close as possible to its native architecture and function. Goal should always be to restore the patients to a state of natural form and function through our surgical interventions [1].

In regenerative medicine, cell therapies are the major interest. The main aim of cell therapy is to replace the biological function of damaged tissue or organs. This can be achieved by the transplantation of isolated and characterized cells to a target organ in sufficient number and quality for them to survive long enough to restore function [2].

Development of technology to enable transplanted cells to be engrafted for a long time is indispensable for maximizing the effects of regenerative medicine. As a simple method appears the transplantation of cells as a single cell suspension, but many cells are known to be lost soon after transplantation, which leads to marginal effects. Tissue engineering is a promising strategy to overcome these problems [3].

2.2 Tissue Engineering

Tissue engineering means the application of principles and methods of engineering and life sciences toward the fundamental understanding of structure-function relationships in normal and pathological mammalian tissues and the development of biological substitutes to restore, maintain or improve tissue function [4].

Tissue engineering combines the use of i) cells, ii) signals and iii) scaffolds for the purpose of tissue/organ repair/regeneration (Figure 1).

- i) The diversity of cell-based applications has dramatically increased with both somatic and stem cell populations being used for tissue engineering. They are being derived from sources throughout the body and our expanding knowledge of cell plasticity and fate has allowed for greater control over their behavior [5].
- ii) Signals means biological factors, which are tissue-inducing substances and plays a critical role in organ morphogenesis and regeneration, and refer to a controlling cell behavior and direct tissue and organ repair [6].
- iii) Engineered scaffolds primarily function as the extracellular matrix holding tissues together, but they have increasingly been used for cell and/or biomolecule delivery as well.

Creating functional multi-tissue constructs is difficult, because generating manner through cell-cytokine-matrix interactions must be controlled over time and space.

In the following will be discussed the combined use of cells, scaffolds, and inductive therapies for tissue engineering.




Figure 1: The triad of cell homing-based tissue engineering. To generate functional biohybrid prostheses from these substantial components, specific biologic signals provide desired phenotypes and behaviour of the cell [7].

2.3 Cells

Cells constitute the fundamental unit of tissues and exhibit a broad spectrum of functional diversity. Two main categories of cellular components will be considered for use in tissue engineering: stem and progenitor cells and mature differentiated cells.

Adult stem cell populations are found in almost every tissue and play a pivotal role in tissue homeostasis [8]. Adult stem cells have the capacity to restore and regenerate tissues and are already programmed to sustain a specific tissue type [9]. Differentiated adult cells perform discrete and highly specialized functions that define a particular tissue. They have the advantage of already being defined toward a specific lineage and do not require specific manipulation to perform a tissue-specific task. By contrast, they lack intrinsic regenerative potential and thus are potentially limited in their usefulness for tissue engineering. Anyway, paracrine communication between stem cells and differentiated cells is likely important to maintain the proper function of each subpopulation and these codependent interactions can potentially be augmented to enhance functional tissue engineering [5].

Stem cell is a cell with the ability for self-renewal and differentiation potential. Self-renewal means asymmetric cell division which leads to at least one daughter cell which is equal to mother cell [10]. Differentiation refers to the ability of a stem or progenitor cell to form a mature lineage cell.

Progenitor cell is partially differentiated cell which can proliferate and has the capacity to differentiate but with no self-renewal ability.

Potency is defined as the ability to differentiate into mature lineage cells and tissues [11]. There are different stem cell types possess varying degrees of potency [10]:

- Totipotent cells – form whole organism, e.g. zygote, a fertilized egg.
- Pluripotent cells – form all germ layers i.e. ectoderm, mesoderm and endoderm, e. g. embryonic stem cells.

- Multipotent cells – form multiple cell lineages which create an entire tissue, usually specific to one germ layer, e.g. adult stem cells - hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs).
- Oligopotent cells – form two or more cell lineages in a tissue, e. g. neuronal stem cells with ability to form different neurone types.
- Unipotent cells – form one cell lineage, e.g. spermatogonial stem cells, intestinal crypt stem cells, follicular bulge skin stem cells.

Plasticity refers to the controversial possibility for adult stem cells to show higher potency in response to different microenvironments. The niche is cellular microenvironment providing support and stimuli to control stem cell properties [10].




Figure 2: Schematic of different stem cell types divided by the potency and their differentiation potential [12].

Other cell types used for tissue engineering include embryonic stem cells (ESCs) which can differentiate into tissues from all 3 germ layers but are complicated by the potential for tumorigenesis and ethical concerns [13]. The development of induced pluripotent stem (iPS) cell technology promises to provide tissue engineers with an entirely new set of tools to fabricate organs [14].

In summary, a diverse population of cells critically maintains normal organ homeostasis and these cells and their interactions must be tightly regulated to successfully engineer functional tissue/organ constructs.

2.4 Signals

While a primary requirement of tissue engineering is to select the optimal cell types and scaffold properties to reconstruct a specific tissue in its particular configuration and function, a pivotal variable for successful regeneration is the cellular microenvironment in which cells and tissue grow [15].

Cell fate is influenced by a number of factors and interactions that require robust control for safe and effective regeneration of functional tissue. Coordinated interactions with cellular microenvironment that cells sense and that performs complex and dynamic regulation of cellular processes. The basis for tissue regeneration, therefore, is the utilization of engineering techniques that mimic the critical aspects of natural healing processes, „the wound healing cascade“ by providing suitable biochemical and physico-chemical factors [16]. The self-healing capacity of patients can be augmented by artificially accelerating the proliferation and differentiation of the recruited or implanted cells via the integration of growth factors (GFs) and cytokines [16], [17]. It is indispensable to provide cells with a local biochemical and mechanical niche mimicking the natural environment in which they can proliferate and differentiate efficiently by creating an artificial extracellular matrix (ECM) and/or by delivering GFs [16], [17], [18], [19], [20], [21], [22]. One fundamental approach to tissue engineering has been to create such an environment to mimic the natural „wound healing cascade“ for induction of regeneration and to accelerate/exploit the inherent capability for tissue regrowth that is generally termed regenerative medicine [16]. Within the complex cascade of biological events, GFs are known to play a central role in information transfer between a wide range of cells and their ECM, and stimulating endogenous repair mechanisms by providing the right signals to cells thereby leading to an accelerated functional restoration of damaged or defective tissues [23], [24], [25], [26].

2.4.1 Platelet-Rich Plasma

Platelet-rich plasma (PRP) is a platelet concentrate in a small volume of plasma that is typically developed from autologous blood [27]. Platelets are cytoplasmic fragments of megakaryocytes and play a central role in the complex process of hemostasis. Clot formation and platelet activation are considered the first steps of the healing process [28]. Within 10 minutes of blood coagulation, platelets release a burst of proteins from their α , δ , and λ granules. These organelles contribute the numerous biologically active molecules that provide platelets with their healing properties. The contents of the α -granule include many growth and differentiation factors that are released upon platelet activation during injury to the vessel wall [29]. The combined effects of these growth factors create an elaborate autocrine and paracrine process, and therefore may result in tissue-specific responses.

Within an hour of activation, 95% of the granule's previously manufactured growth factors will be secreted. The platelets then sustain production of additional growth factors over the next several days [30].

For the platelets to release this cascade of molecules that contribute to tissue healing, they must first be activated. Some studies activate PRP with thrombin and or calcium [31]. Once activated, the resulting PRP mixture must be injected immediately, as the subsequent secretion of the granule contents occurs rapidly. The addition of thrombin and calcium to the platelet mixture produces a gel that cannot be injected even using a large gauge needle, thus limiting its use in certain surgical procedures.

The application of soluble type-I collagen has been evaluated as an alternative to thrombin and calcium in platelet activation. Activation via type-I collagen produces a less rapid release of the granule contents, which enable a delayed administration of PRP. When compared with thrombin activation, the collagen-activated platelets produced equal concentrations of particular growth factors with less clot retraction. The collagen activation technique also

permits in vivo activation that can be administered through a small-gauge needle. These results suggest that type-I collagen may be an effective method for platelet activation [32].

2.4.1.1 Growth Factors in PRP

Benefits of this therapy with PRP at the molecular level include the intrinsic properties of its growth factors. It is important to note that growth factors are not the only elements present in significant concentrations in PRP, as proteins of the cytokine and chemokine families are known to be present in varying concentrations as well. The elements identified in PRP include TGF β , vascular endothelial growth factor (VEGF), platelet-derived endothelial growth factor, epidermal growth factor, insulin-like growth factor, platelet factor 4, IL-1, platelet-derived angiogenesis factor, epithelial cell growth factor, osteocalcin, osteonectin, thrombospondin-1, fibrinogen, fibronectin, and vitronectin. The concentrations of these various growth factors increase linearly as platelet concentration increases [29], [33]. The network of activated growth factors induces intracellular signaling pathways that lead to the production of proteins essential to the regenerative processes, such as cell proliferation, matrix formation, osteoid production, and collagen synthesis [34].

Cell types that are involved in the healing process, such as osteoblasts, fibroblasts, epithelial cells, endothelial cells, and adult mesenchymal stem cells reveal the presence of membrane receptors that are specific for certain growth factors. Furthermore, when cytokines are released they bind to the transmembrane receptors on the surface of local or circulating cells [28], [35]. At the time of injury, the platelets arrive via the capillaries and are activated, releasing their granule contents into the wound site. This influx of growth factors and proteins play an active role in synthesizing the necessary components for the regenerative process and may also play a paracrine role by recruiting other cells to the wound site.

A summary of these growth factors, their role in the healing process are presented in Table 1.

Table 1: Effect of the growth factors produced by platelets [36].

Growth factor	Effect
PDGF (platelet-derived growth factor)	Macrophage activation and angiogenesis Fibroblast chemotaxis and proliferative activity Enhances collagen synthesis Enhances the proliferation of bone cells
TGF- β (transforming growth factor- β)	Enhances the proliferative activity of fibroblasts Stimulates biosynthesis of type I collagen and fibronectin Induces deposition of bone matrix Inhibits osteoclast formation and bone resorption
IGF-1 (insulin-like growth factor-1)	Chemotactic for fibroblasts and stimulates protein synthesis Enhances bone formation by proliferation and differentiation of osteoblasts
PDEGF (platelet-derived endothelial growth factor)	Promotes wound healing by stimulating the proliferation of keratinocytes and dermal fibroblasts
PDAF (platelet-derived angiogenesis factor)	Induces vascularization by stimulating vascular endothelial cells
PF-4 (platelet factor-4)	Stimulates the initial influx of neutrophils into wounds A chemoattractant for fibroblasts A potent antiheparin agent
EGF (endothelial growth factor)	Cellular proliferation Differentiation of epithelial cells
VEGF (vascular endothelial growth factor)	Angiogenesis Migration and mitosis of endothelial cells Creation of blood vessel lumen Creates fenestrations Chemotactic for macrophages and granulocytes Vasodilation (indirectly by release of nitrous oxide)

2.4.1.2 Preparation of Platelet-Rich Plasma

The whole blood which is a mixture of cells, colloids and crystalloids can be separated into different blood components namely packed red blood cell (PRBC) concentrate, platelet concentrate, fresh frozen plasma and cryoprecipitate [27], [37].

In increasing order, the specific gravity of blood components is plasma, platelets, leucocytes (Buffy Coat [BC]) and packed red blood cells (PRBCs) [38].

The components are prepared by centrifugation of one unit of whole blood. Single component required can also be collected by apheresis procedure in blood donors.

Different platelet concentrates can be classified into four categories, depending on their leucocyte and fibrin content:

- pure platelet-rich plasma (P-PRP),
- leucocyte- and platelet-rich plasma (L-PRP),
- pure platelet-rich fibrin (P-PRF),
- leucocyte and platelet-rich fibrin (L-PRF).

All available PRP techniques have some points in common:

Blood is collected with anticoagulant just before or during surgery and is immediately processed by centrifugation. The time for platelet concentrate preparation is variable but is always completed within an hour. A first centrifugation step is designed to separate the blood into three layers, red blood cells (RBCs) are found at the bottom, acellular plasma (PPP, platelet-poor plasma) is in the supernatant and a 'buffy coat' layer appears in between, in which platelets are concentrated (Figure 3). The next steps vary among the numerous

protocols but are an attempt to discard both the RBC layer and the PPP to collect only the ‘buffy coat’ layer. Finally, the obtained platelet concentrate is applied to the surgical site with a syringe, together with thrombin and/or calcium chloride (or similar factors) to trigger platelet activation and fibrin polymerization.

In Choukroun’s PRF (platelet-rich fibrin) preparation is blood collected without any anticoagulant and immediately centrifuged. A natural coagulation process then occurs and allows for the easy collection of a leucocyte- and platelet-rich fibrin (L-PRF) clot, without the need for any biochemical modification of the blood, that is, no anticoagulants, thrombin or calcium chloride are required [39].




Figure 3: Classical manual platelet-rich plasma (PRP) protocol using a two-step centrifugation procedure [40].

2.4.1.3 Platelet Lysate

Platelets constitute a potential source of multiple GFs and proteins involved in tissue regeneration. Some of GFs are available in purified form, but it has been pointed out that tissue repair cannot be effectively mediated by a single agent, as multiple signals are required to complete the regeneration process. Moreover it is also recognized that the efficacy of the GFs critically depends on the way they are made available to the injured tissue [41].

Platelet-rich preparations are hemoderivatives, from which platelets can release their complete pool of biologically active substances. Among these hemoderivatives is platelet-rich plasma (PRP), which can be obtained from the patient (autologous) or from donors (allogenic) [42], [43], [44], [45].

The platelet concentrate can therefore be activated by adding thrombin or calcium to form a three-dimensional and biocompatible fibrin scaffold (fibrin glue). The term ‘releasate’ is usually used to describe the preparations, which consist of bioactive molecules in a solution obtained by activation of platelets with calcium or thrombin, while the term ‘lysate’ indicates the solution of bioactive molecules obtained by platelet destruction by freeze-thawing, usually starting from a PRP sample in the presence of an anticoagulant agent [46].

Platelet lysate promotes keratinocyte epithelialization and regulates fibroblast matrix deposition, providing a molecular basis for the capability of such hemoderivative to heal severe and problematic wounds [47].

Platelet lysate loaded in gel and sponge-like dressings intended for the treatment of mucosal, corneal and skin lesions. Such formulations were capable to enhance in vitro proliferation of fibroblasts and corneal (RCE) cells [48], [49], [50], [51], [52].

2.5 Scaffold

Tissue engineering technologies are based on the biological triad and involve the successful interaction between three components: (1) the scaffold that holds the cells together to create the tissue's physical form; (2) the cells that create the tissue; and (3) the biological signalling molecules, such as growth factors, that direct the cells to express the desired tissue phenotype [53].

Scaffold is the central component that is used in tissue engineering to deliver cells, drugs, and genes into the body. They are most commonly recognized as defined structure biomaterials potentially able to perform useful functions:

- (i) promoting cell attachment, survival, proliferation and differentiation while possessing minimum toxicity in the original and biodegraded forms;
- (ii) allowing the transport or delivery Of gases, nutrients and growth factors;
- (iii) offering sufficient structural support while being degradable at appropriate rates for tissue regeneration [54].

The scaffolds provide a three-dimensional structure for cell adhesion, proliferation, differentiation, and secretion of extracellular matrices to guide new tissue formation and regeneration [55]. These scaffolds essentially act as a template for tissue formation and are typically seeded with cells and occasionally growth factors, or subjected to biophysical stimuli in the form of a bioreactor; a device or system which applies different types of mechanical or chemical stimuli to cells [56].

These cell-seeded scaffolds are either cultured in *vitro* to synthesize tissues which can then be implanted into an injured site, or are implanted directly into the injured site, using the body's own systems, where regeneration of tissues or organs is induced in *vivo* [1].

When cells are implanted or seeded into an artificial structure capable of supporting three-dimensional (3D) tissue formation, these structures are called "cell delivery scaffolds," and when drugs are loaded into a 3D artificial porous structure capable of high drug loading efficiency and sustained release of a drug for longer duration, they are called "drug delivery scaffolds" [57].

Different forms of polymeric scaffolds for cell/drug delivery are available (Figure 4):

- (i) 3D porous matrix – a highly porous and well interconnected open pore structure that allows high cell seeding density and tissue in-growth; (ii)
- (ii) nanofibrous matrix – prepared by electrospinning or self-assembly would provide a better resemblance of the physiological environment [56], [58];
- (iii) thermosensitive sol-gel transition hydrogel - physically or chemically cross-linked, water-soluble polymers, which swell to form a gel like substance on exposure to water [59];
- (iv) porous microsphere and microparticles - delivering biomolecules such as growth factors, genes, and cells [60].




Figure 4: Different forms of polymeric scaffolds for tissue engineering [61].

These are already widely utilized as sustained protein-release formulations and have been applied in tissue engineering for the potential use as a cell delivery carrier or supportive matrix [62], [63].

Of the polymeric scaffolds a typical 3D porous matrix and nanofibrous matrix are the implantable forms and a thermosensitive sol-gel transition hydrogel and porous microsphere are the injectable forms [64].

2.5.1 Properties of Scaffold Matrices

An ideal tissue engineering scaffold (cell delivery) should fulfill the following requirements [65]:

- mechanical properties that are sufficient to shield cells from tensile forces without inhibiting biomechanical cues,
- desired volume, shape, and mechanical strength [58],
- acceptable biokompatibility
- a highly porous and well-interconnected open pore structure to allow high cell seeding density and tissue in-growth
- bioadsorption at predetermined time period
- biocompatible chemical compositions and their degradation products,
- causing minimal immune or inflammatory responses [66],
- physical structure to support cell adhesion and proliferation,
- facilitating cell–cell contact and cell migration [64].

In the section below we will learn more about desired properties.

Mechanical properties of the scaffold should match those of the tissue at the implantation site, or the mechanical properties at least should be sufficient to shield cells from damaging compressive or tensile forces without inhibiting appropriate biomechanical cues [64], [67] and to survive under physiological conditions [53].

Mimicking the native extracellular matrix (ECM), an endogenous substance that surrounds cells, allows them to bind into tissues and provide signals that aid cellular development and morphogenesis [64].

The scaffold should possess relatively easy processability and malleability into the desired shape, according to the need. They should be capable of being produced into a sterile product.

The scaffold should possess acceptable biocompatibility and toxicity profiles. Cells must adhere, function normally, and migrate onto the surface and eventually through the scaffold and begin to proliferate before laying down new matrix. After implantation, the scaffold must elicit a negligible immune reaction in order to prevent it causing such a severe inflammatory response that it might reduce healing or cause rejection by the body [1].

It should have a reproducible microscopic and macroscopic structure with a high surface: volume ratio suitable for cell/drug attachment [68]. Scaffolds should have an interconnected pore structure and high porosity to ensure cellular penetration and adequate diffusion of nutrients to cells within the construct and to the extra-cellular matrix formed by these cells. A porous interconnected structure is also required to allow diffusion of waste products out of the scaffold [1]. Cells primarily interact with scaffolds via chemical groups (ligands) on the material surface. Scaffolds synthesized from natural extracellular materials (e.g. collagen) naturally possess these ligands in the form of Arg-Gly-Asp (RGD) binding sequences, whereas scaffolds made from synthetic materials may require deliberate incorporation of these ligands through another mechanism, for example, protein adsorption. The ligand density is influenced by the specific surface area. This depends on the mean pore size in the scaffold. The pores thus need to be large enough to allow cells to migrate into the structure, but small enough to establish a sufficiently high specific surface, leading to a minimal ligand density to allow efficient binding of a critical number of cells to the scaffold [64].

The scaffold should have a maximum loading capacity so the drug is released continuously for longer duration after insertion into the body. The drug release from the scaffold needs to be controlled to allow the appropriate dose of drug to reach the cells over a given period of time.

Binding affinity must be sufficiently low to allow release of the drug.

They should possess dimensional stability, chemical stability, and biological activity over a prolonged period of time [57].

The scaffold material should be biodegradable, its degradation products should not be toxic and should be eliminated easily from the implantation site by the body [53], eliminating the need for further surgery to remove it [69]. The scaffold's degradation rate should be adjusted to match the rate of tissue regeneration so that it has disappeared completely once the tissue is repaired [68].

The matrix material of the scaffold should be biodegrade at a controllable rate that approximates the rate of natural tissue regeneration and should provoke a minimal immune and/or inflammatory response in vivo [53]. Tissue engineering scaffolds are meant to be colonized by cells and should transmit the chemical and physical cues necessary to ensure adequate tissue growth. Synthetic polymer scaffolds may be used to deliver proteins and growth factors with or without cells locally to enhance tissue repair and regeneration [57].

2.6 Biomaterials for Scaffolds

There are three individual groups of biomaterials: ceramics, synthetic polymers and natural polymers, in the fabrication of scaffolds for tissue engineering.

2.6.1 Natural Polymers

Natural polymers often possess highly organized structures and may contain an extracellular substance, called ligand, which can be bound to cell receptors and they exhibit biological activity and typically promote excellent cell adhesion and growth. They are also biodegradable and so allow host cells, over time, to produce their own extracellular matrix and replace the degraded scaffold [71]. However, as natural polymers can guide cells to grow at various stages of development, they may stimulate an immune response at the same time. This leads to concerns over antigenic and delivery of diseases for allograft [72].

Natural polymers include alginate, proteins, collagens, gelatin, fibrins, albumin, elastin, pectin (pectinic acid), galactan, curdlan, gellan, levan, emulsan, dextran, pullulan, gluten, elastin, fibroin, hyaluronic acid, cellulose, starch, chitosan (chitin), scleroglucan, heparin, silk, chondroitin 6-sulfate, and polyhydroxyalkanoates [73].

Calcium Oxidized Cellulose

Cellulose is a polysaccharide synthesized by grasses, woody plants, many forms of algae, fungi and some species of bacteria, namely *Acetobacter xylinum*. Bacterial cellulose is identical to plant cellulose in chemical structure, but it can be produced without contaminant molecules, such as lignin and hemicelluloses, and does not require intensive purification processes. In addition, it is remarkable for its mechanical strength and biocompatibility, so it has often been applied in tissue engineering [74].

Cellulose in the human organism behaves as a non-degradable or very slowly degradable material. An efficient method for inducing degradability of cellulose is its oxidation.

Oxidized cellulose can be generated by various techniques and by various oxidizing agents, such as NaClO_2 , CCl_4 , nitrogen oxides or free nitroxyl radicals (TEMPO oxidation) [75], [76], [77].




Figure 5: Oxidation process of cellulose by NO_2 gas [78].

Oxidized cellulose is degradable by hydrolysis, by mediated hydrolytic enzymes present in the serum supplement of cell culture media in vitro, and in vivo, in macrophages [79].

Cellulose oxidation induces conversion of the glucose residues to glucuronic acid residues containing $-\text{COOH}$ groups. The $-\text{COOH}$ groups, which are polar and negatively charged, can be used for functionalizing the oxidized cellulose with various biomolecules [80].

Oxidized cellulose has been widely used as a wound healing material with excellent properties, such as high absorbability, antibacterial and antiviral properties, and non-toxic and antiadhesive effects [81]. Due to its ability to initiate or accelerate blood coagulation at the site where it is applied, oxidized cellulose has been used as a hemostatic material [82].

Chitosan

Chitosan is another biomaterial used in a variety of biomedical fields such as drug delivery carriers, surgical thread, and wound healing materials [83]. It is derived from chitin, is

an abundant polysaccharide that may be used to replace glycosaminoglycan [84]. Due to its many advantages for wound healing such as hemostasis, accelerating the tissue regeneration and the fibroblast synthesis of collagen, many applications of chitosan in skin tissue engineering have been reported [85]. In addition, chitosan can function as a bridge to increase the cross-linking efficiency of GA in the collagen-based scaffolds owing to the large number of amino groups in its molecular chain (Figure 6). Hence, one can expect that less GA could be used in the presence of chitosan and the potential cytotoxicity of GA might be decreased [86].




Figure 6: Schematic presentation of collagen cross-linked with glutaraldehyde in the presence of chitosan [86].

Chitin/Chitosan-Glucan Complex

Fungal mycelial wastes from biotechnological plants can become free and rich alternative sources of chitin/chitosan materials, beside the traditional industrial source – shellfish waste materials. Moreover, the fungal chitosans can have unique properties compared with those derived from Crustacea. It have been tested possibilities of production and some applications of chitin-glucan complex and chitosan from industrial waste mycelia of *Aspergillus niger* from a citric acid production plant and *Penicillium oxalicum* from production of a red anthraquinone dye in Czech Republic. The alkali-insoluble cell-wall residue of the mycelia consists mainly of chitosan, chitin and β -glucans, with a significant preponderance of (1 \rightarrow 3)- β -D-glucan. Chitin is thought to be present as microfibrils physically embedded in the β -glucan matrix. The formation of the chitin/chitosan–glucan complex chains results in a rigid cross-linked network in the cell wall and causes a considerable problem for the extraction of intact chitosan and glucan [87].

2.6.2 Synthetic Polymers

Synthetic polymers are man-made polymers, which have the advantages over the use of natural origin polymers as they are more flexible, more predictable and processable into different size and shapes and have no immunogenicity [53]. The physical and chemical properties of a polymer can be easily modified and the mechanical and degradation characteristics can be altered by their chemical composition of the macromolecule. The functional groups and side chains of these polymers can be incorporated, i.e. the synthetic polymers can be selfcross-linked or cross-linked with peptides or other bioactive molecules.

Additionally, synthetic polymers are generally degraded by simple hydrolysis that is desirable as the degradation rate does not have variations from host to host, unless there are inflammations and implant degradation etc. to affect the local pH variations [72].

Synthetic polymers are largely divided into two categories: biodegradable and nonbiodegradable.

Biodegradable polymers are polyglycolide (PGA), polylactide (PLA) and its copolymer poly(lactide-*co*-glycolide), polycaprolactone (PCL), polyethylene glycol (PEG), polyphosphazene, polyanhydride, poly(propylene fumarate), polycyanoacrylate, polycaprolactone, polydioxanone, and polyurethanes.

Nonbiodegradable polymers include polyvinyl alcohol, polyhydroxyethylmethacrylate, and poly(*N*-isopropylacrylamide).

2.6.3 Bioceramics

Melting inorganic raw materials to create an amorphous or crystalline solid body is known as *bioceramics*, and these porous final products are used mainly for scaffolds.

Ceramic scaffolds are typically characterized by high mechanical stiffness (Young's modulus), very low elasticity, and a hard brittle surface. Ceramics are known to enhance osteoblast differentiation and proliferation [88], [89].

Bioceramics classified as (i) nonresorbable (relatively inert), for example alumina, zirconia, and silicon nitride; and (ii) bioactive or surface active (semi-inert), for example glass ceramics such as dense hydroxyapatites [$9\text{CaO} \cdot \text{Ca}(\text{OH})_2 \cdot 3\text{P}_2\text{O}_5$], and biodegradable or resorbable (noninert) such as calcium phosphates, aluminium calcium phosphates, coralline, tricalcium phosphates ($3\text{CaO} \cdot \text{P}_2\text{O}_5$), zinc calcium phosphorus oxides, zinc sulphate calcium phosphates, ferric calcium phosphorus oxides, and calcium aluminates [53].

Collagen-based scaffolds can be also strengthened by introducing a ceramic phase [90]. These scaffolds not only possess significantly increased mechanical properties while retaining the highly porous and interconnected pore structure [91], but also show improved permeability which benefits cell infiltration and subsequent vascularization.

2.6.4 Biocomposites

Because each of the individual biomaterial groups has specific advantages and disadvantages, so the use of composite scaffolds comprised of different phases is becoming increasingly common. Composite scaffolds consists of at least one phase which is not found naturally in the body and they all have associated problems with biocompatibility, biodegradability or both. A more typical approach is the use of collagen-based scaffolds, either alone or with an additional phase incorporated to enhance biological and/or mechanical properties [71].

Combinations of (1) synthetic–synthetic, (2) synthetic–natural and (3) natural–natural polymers have ability to tailor mechanical, degradation, and biological properties but compromise the “best” qualities of individual polymers with properties of the overall scaffold [53].

2.7 Collagen

Collagen had been defined as a family of proteins located in the extracellular matrix of connective tissue that provides a structural basis for the mechanical and biochemical properties of tissues and organs [92].

Several distinct types of collagen had been identified, which collectively, represent about one third of the total protein of vertebrate animals. As a function of structure and supramolecular organization, they were grouped as fibril-forming (types I, II, III, V, XI), fibril-associated (types IX, XII, XIV), membrane (types IV, VII, VIII, X) or other specific function. The fibril-forming collagens are the major structural element of connective tissue, providing the scaffold that gives stability and integrity to tissues and organs [67].

2.7.1 Structure of Collagen

The collagen molecule consists of three polypeptide subunits known as α -chains twined around one another as in a three-stranded rope. Each chain has an individual twist in the opposite direction. The principal feature that affects a helix formation is a high content of glycine and amino acid residues. The strands are held together primarily by hydrogen bonds between adjacent $-\text{CO}$ and $-\text{NH}$ groups and also by covalent bonds [93].

Currently, 29 distinct collagen types have been characterized and all display a typical triple helix structure [94] which vary in the length of the helix and the nature and size of the nonhelical portions. Type I collagen is predominant in higher order animals especially in the skin, tendon, and bone where extreme forces are transmitted, and also has the advantage of possessing lower antigenic and hypoallergenic properties, therefore it is used as standard in the field of tissue-engineering.

It is a compound of three chains, two of which are identical, termed $\alpha 1(\text{I})$, and one $\alpha 2(\text{I})$ chain with different amino acid composition or it can rarely represent a trimer built of three $\alpha 1(\text{I})$ chains. The basic collagen molecule contains three polypeptide α -chains, each consisting of more than one thousand amino acids [95]. Glycine has the smallest side group and its presence is essential at every third amino acid position in order to allow for a tight packaging of the three α -chains in the tropocollagen molecule and the X and Y positions are mostly filled by proline and 4-hydroxyproline (Figure 7a) [94], [96].




Figure 7: Chemical structure of collagen type I. (a) Primary amino acid sequence, (b) secondary left handed helix and tertiary right handed triple-helix and (c) staggered quarternary structure [96].

Collagen also contains the unusual amino acid hydroxylysine. Formation of hydroxylysyl residues allows the attachment of sugar components, an unalterable requirement

for the collagen molecule to form a triple-helical structure. Both imino acids stabilize the triple helix. Due to their alicyclic nature, they stiffen the α -chain and form hydrogen-bonds limiting rotation [97].

The unique physiological and biomaterial characteristics of collagen compared with most synthetic polymers derive from the structural complexity of the collagen molecule. There are observed the various levels of order in collagen. [98] The tertiary structure refers to the fundamental unit originally known as tropocollagen: three polypeptide chains intertwined to form a right-handed triple-helix with a pitch of approximately 8.6 nm.

The rod-shaped triplehelix has an average molecular weight of approximately 300 kDa, a length of 300 nm with a diameter of 1.5 nm (Figure 7) [99].

There are regions of 9–26 amino acids at the amino and carboxyl terminal chain ends of the molecule that are not incorporated into the helical structure. These non-helical regions are denoted as telopeptides. On the fourth level of order, the triple-helical molecules associate of individual triple helices longitudinally and bilaterally into fibrils with distinct periodicity.

The collagen molecules aggregate through fibrillogenesis into microfibrils consisting of four to eight collagen molecules and further into fibrils. Those fibrils reach from 10 to 500 nm in diameter depending on tissue type and stage of development [99].




Figure 8: Overview of the collagen triple helix. (a) First high-resolution crystal structure of a collagen triple helix. (b) View down the axis of a (ProProGly) triple helix with the three strands depicted in space-filling, ball-and-stick, and ribbon representation. (c) Ball-and-stick image of a segment of collagen triple helix, highlighting the ladder of inter strand hydrogen bonds. (d) Stagger of the three strands in the segment in panel c [100].

Collagen pro- α chain is synthesized from a unique mRNA within the rough endoplasmic reticulum and is then transferred to the Golgi apparatus of the cell. During this transfer, some prolines and lysines residues are hydroxylated by the lysyl oxydase enzyme. Specific lysines are glycosylated and then pro- α -chains self-assemble into procollagen prior to their encapsulation in excretory vesicles. Following their passage through the plasma membrane, the propeptides are cleaved outside the cell to allow for the auto-polymerisation by telopeptides. This step marks the initiation of tropocollagen self-assembly into fibril and the agglomeration of fibril into collagen fibers. Fibril-forming collagens are the most commonly used in the production of collagen-based biomaterials [101].

2.7.2 Physical and Chemical Propetries

2.7.2.1 Natural Crosslinks

Mechanical and chemical stability derives from intra- and intermolecular crosslinks. Initially, the formation of crosslinks is mediated by lysyl oxidase during fibril formation [102].

The enzymatic activity is limited to the non-helical telopeptide regions and leads to the conversion of selective lysyl and hydroxylysyl residues to the corresponding aldehydes allysine and hydroxyallysine (Figure 9). While the fibrils associate, the aldehydes can spontaneously react. Intramolecular crosslinks form between two α -chains in the non-helical section of the same molecule by aldol condensation of two aldehydes [102], [103]. Intermolecular crosslinks occur between the telopeptide region of one collagen molecule and the helical region of a quarterly staggered, adjacent molecule. These bridges between two different tropocollagen molecules result from aldimine formation (non-, mono- or dihydroxylated dehydrolysinonorleucine (D-HLNL)) between aldehyde residues and ϵ -amino groups presented by lysine and hydroxylysine (Figure 9). The interchain bifunctional crosslinks are still reactive and continue to form polyfunctional crosslinks through multiple condensations with histidine, lysine, or hydroxylysine residues [104]. Besides the formation of enzymatic crosslinks there is a group of crosslinks derived from glycated lysine and hydroxylysine residues which occur more adventitiously [103]. Hence, through specific self-aggregation and crosslinking, collagen can form fibers of unusual strength and stability. The degree of crosslinking increases with age and stress [105] and consequently changes the properties of collagen material.




Figure 9: Chemical structures of natural collagen crosslinks. (a) Oxidation of lysine and hydroxylysine via lysyl oxidase, (b) intramolecular aldol condensation type crosslink, (c) intermolecular aldimine (Schiffs' base) type crosslink (R1, R2=H, OH: dehydrolysinonorleucine, dehydrohydroxylysinonorleucine, dehydrodihydroxylysinonorleucine (may undergo Amadori rearrangement to form ketoamine)), (d) condensation of aldol condensation type crosslink with hydroxyproline (can further condensate with lysyl residue to form histidinohydroxymerodesmosine) and (e) hydroxypyridinium type crosslink [96].

2.7.2.2 Degradation

Collagen is particularly resistant to attacks by neutral proteases. At neutral pH only specific collagenases cleave the native helix at a position, about threequarters of the way from the N-terminus [106]. Fibrils as aggregates of collagen molecules are degraded starting from the exterior.

Administration of exogenous collagen activates a complex cellular response which depends on the type of collagen material. Collagen degradation by all these cell types can occur either after phagocytosis of partially cleaved fibers or by extracellular proteases acting at either neutral or acid pH. Activation of macrophages has been shown to cause a pH decrease in the micro-environment of collagen implants to below pH 5 [107]. Together with the excretion of cathepsin from macrophages and neutrophils [108] this creates an acidic pathway for collagen breakdown.

In vitro degradation is usually simulated by incubation with bacterial collagenase, cathepsin, pepsin or trypsin [109].

2.7.2.3 Antigenicity and Immunogenicity

Selective removal of the non-helical component from the collagen molecule suppresses its antigenicity [110]. Additional chemical crosslinking, e. g. with glutaraldehyde reduces the antigenicity but does not eliminate it completely [111]. Thus, the immunogenic response depends on the collagen source as well as the test technique and the species used for animal experiments [112]. Despite theoretical concerns animal collagen in the form of sutures, hemostatic agents, and injectable collagen is considered safe [113] and only mildly antigenic [114], making it suitable for use as an implantable and injectable biomaterial.

2.7.2.4 Solubility for Isolation and Purification of Collagen

The major impediment to dissolution of collagen type I from tissue is the presence of covalent crosslinks between molecules. Collagen is insoluble in organic solvents. Watersoluble collagen represents only a small fraction of total collagen. The nature of the crosslinks prevalent in different tissues determines the particular solvent to be used and the corresponding yields.

The most commonly used solvents are neutral salt solution (0.15–2 M NaCl) or dilute acetic acid [115].

Dilute acidic solvents, e.g. 0.5 M acetic acid, citrate buffer, or hydrochloric acid pH 2–3 are more efficient than neutral salt solutions. The intermolecular crosslinks of the aldimine type are dissociated by the dilute acids and the repulsive repelling charges on the triple-helices lead to swelling of fibrillar structures [116].

It is possible to solubilize approximately 2 % of the tissue collagen with dilute salt or acid solutions. These collagen molecules can be reconstituted into large fibrils with similar properties as native fibrils by adjusting the pH or temperature of the solution [109].

The remaining 98 % is referred to as insoluble collagen although this dominant collagen material is not absolutely insoluble and can be further disintegrated without major damage to the triple-helical structures. The two most common approaches are the use of strong alkali or enzymes to cleave additional crosslinks and suspend or dissolve at first acid-insoluble structures.

Instead of disintegration and transfer into soluble material, extensively crosslinked collagen can be dispersed as opalescent, fine fibrillar suspensions by the use of mild denaturation agents and mechanical fragmentation usually at an acidic pH.

In additional steps collagen material can be subjected to chemical modifications such as succinylation [117], acetylation [118], methylation [119] or attachment to other polymers [120].

2.7.3 Crosslinking

In common with all natural polymers, one major problem with using collagen as the main constituent of a scaffold for orthopedic tissue engineering is that it has relatively poor mechanical properties. Natural crosslinking gives high tensile strength and proteolytic resistance to collagen. Dissociation of crosslinks can lack sufficient strength and may disintegrate upon handling or collapse under the pressure from. Therefore, it is often necessary to confer mechanical firmness and collagenase resistance by introduction of exogenous crosslinking into the molecular structure [121], [122].

Cross-linking of the collagen-based scaffolds is an effective method to modify the biodegrading rate (enzymatic resistance) and to optimize the mechanical property for implantation purposes. The principle of a cross-linking reaction relies on the modification of amine and carboxyl groups within the collagen molecules, to allow the formation of covalent bonds. Several methods have been developed to cross-link collagen scaffolds. These polymerization techniques are distributed among three types: physical, chemical and enzymatic crosslinking.

An alternative to covalent bond crosslinking is to promote the formation of ionic bonds between collagen molecules. This can be achieved by polycationic molecules such as chitosan, which create ionic bonds between its numerous amine groups and the carboxyl groups of collagen. These bonds are strong enough to stabilize the biomaterial structure and form a strong mechanical strength [123], [124]. The major advantage of this technique is to prepare the biomaterial in a one step process, where chitosan is mixed with collagen before freeze-drying, avoiding the need of further washing steps since chitosan is not toxic [125].

Enzymatic crosslinking agents like transglutaminase can be used to enhance tensile strength and enzymatic resistance of collagen-based biomaterial [126], [127], [128]. The major advantage with the approach of using a biologic polymerization technique is that no chemical residues or by-products remain in the scaffold structure, and therefore eliminate the risk of inducing cytotoxic effects.

A plethora of biomolecules can also be added to collagen solution to produce collagen-based biomaterials. These biomolecules, typically GAG, elastin and chitosan are added to the compound to potentially enhance the mechanical strength and to modulate cellular functions such as migration, proliferation and differentiation [129], [130], [131], [132], [133], [134], [135].

2.7.3.1 Physical Treatment

Alternative physical methods are pursued, including dry heat, exposure to ultraviolet or γ -irradiation, because chemical crosslinking agents is the potential toxic effect of residual molecules and/or compounds formed during in vivo degradation [136]. Collagen becomes partially denatured by these physical treatments [137]. In order to keep degradation

of the triple-helices to a minimum it is crucial for dehydrothermal (DHT) treatment to reduce the water content via vacuum as thoroughly as possible prior to heating [138]. Severe dehydration itself already induces amide formation and esterification between carboxy and free amino and hydroxyl groups, respectively [139], [140]. The combination of degradation and crosslinking allows non-specific enzymes to attack and solubilize fragments of the crosslinked material. Formation of crosslinks during UV-irradiation is thought to be initiated by free radicals formed on aromatic amino acid residues [137] which indicates a rather limited maximum degree of crosslinking due to the small number of tyrosine and phenylalanine residues in collagen.

2.7.3.2 Synthetic Crosslinkers

Due to the large number of functional side groups it contains, collagen readily undergoes chemical crosslinking. This is usually performed using bifunctional reagents as glutaraldehyde (GTA), dialdehydes and diisocyanates, as well as carbodiimides, diepoxides, polyepoxy compounds, formaldehyde and acyl azide methods [141], [142], [143], [144].

Using this agents it is possible to create a three-dimensional network that results in collagen scaffolds with enhanced mechanical properties. However, glutaraldehyde and 1,6-hexamethylene diisocyanate have been found to be cytotoxic and as such carbodiimide or acyl azide methods have been introduced [145], [146]. However, both methods have limited cross-linking ability due to their short length structure and inability to polymerise [147].

Carbodiimides

Crosslinking with carbodiimides, especially 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) offers the main advantage over aldehydes, HDC, or epoxy compounds in that these carbodiimides only facilitate the formation of amide bonds between carboxylic and amino groups on the collagen molecules without becoming part of the actual linkage. Thus, bifunctional crosslinking agents are obviated. Carbodiimides first couple to a carboxylic group to form *o*-isoacylurea structures. The resulting activated intermediate is attacked by a nucleophilic primary amino group to form an amide crosslink and the isourea derivative of the applied carbodiimide is eliminated and can be washed out [148], [149]. The susceptibility of carbodiimide crosslinked material to enzymatic degradation can be controlled by varying the degree of cross-linking via the reaction conditions [150].

Nowadays it is most commonly used *N*-ethyl-*N'*-[3-dimethylaminopropyl]carbodiimide/*N*-hydroxy succinimide (EDC/NHS) as a non-toxic cross-linker which crosslinks without incorporation of the crosslinking reagent [82]. 1-Ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC) or acylazide were used to generate peptide-like bonds in biomaterials [151]. Use of EDC and *N*-hydroxysuccinimide (NHS) to crosslink collagen seems to yield biomaterials with good biocompatibility, higher cellular differentiation potential and with increased resistance against enzymatic degradation [152].




Figure 10: Schematic reaction of collagen with EDC/NHS.

2.7.3.3 Natural Cross-linking Agents

The syntetic substances for cross-linking are tried to be replaced by crosslinking agent able to form stable and biocompatible crosslinked products, without added cytotoxicity problems. This is the reason of the increasing demand for natural crosslinking agents for medical applications [153]. Natural crosslinkers have high biological activity and can significantly improve collagens properties while preserving its triple-helical structure [154].

Recent data demonstrate that plant extracts not only optimally stabilise collagen scaffolds and bring about mechanical properties similar to native extracellular matrix assemblies, but also do not compromise cell attachment, proliferation and growth [155], [156], [157], [158], [159], [160], [161], [162], [163].

Genipin is a natural cross-linking agent found in plants, which has been shown to be quite efficient in protein cross-linking [164]. Using citric acid as a crosslinked molecule will avoid inducing toxic substances. CA can easily react with the amidogen on the collagen chain and form cross-links to enhance the mechanical strength [165]. Stabilisation using *M. rubra* could be a valuable alternative to aldehyde approaches for the construction of three-dimensional scaffolds that would imitate native extracellular matrix assemblies [166]. The interactions between protein and polyphenol can involve hydrogen bond, covalent linkage, ionic and hydrophobic bonding. The hydrogen bond interaction is mainly responsible for the stabilization of collagen by procyanidin. The procyanidin treatment does not destroy the triple helix conformation of collagen, but induces the aggregation of collagen microfibrils [167].

2.8 Scaffold Fabrication Techniques

In the last decade, various fabrication methods for construction of three-dimensional biomimetic scaffolds, including electrospinning [168], [169], [170], phase-separation [171], [172], freeze drying [173], [174] and self-assembly [175], [176] have been developed for tissue engineering and regenerative medicine. These scaffolds can mimic the architecture of the native extracellular matrix at the nanoscale level (eg, hierarchical architecture formed with nanofibers and nanopores), which provides the initial space for regeneration of new tissue [177].

In addition, surface modification methods (eg, plasma exposure) used for nanostructured scaffolds can introduce functional groups (e. g. Arg-Gly-Asp peptide) onto the surface of the scaffolds, which directly and significantly enhance cell attachment, migration, and proliferation.

Traditional tissue engineering methods use a “top-down” approach, in which cells are seeded onto a scaffold with biocompatible and biodegradable properties, and are expected to populate in the scaffold and create their own extracellular matrix. Despite several thin or avascular tissues, such as skin [178], bladder [179], and cartilage [180], having been engineered successfully via the top-down approach based on these biomimetic scaffolds in vitro, the fabrication of complex larger functional tissues (eg, liver and kidney) with high cell densities and high metabolic requirements still faces challenges. This is mainly because of the limited diffusion properties of biomimetic scaffolds [181].

Tissue engineered constructs can also be fabricated by the assembly of smaller building blocks. This approach mimics much of the native biology that is often made from repeating functional units. For example, in the liver, the sinusoid is the repeating functional unit. Bottom-up approaches can be used to generate functional units that can be assembled in a modular approach to generate larger scaffolds [182]. Fabrication of tissue building blocks can be achieved via multiple approaches, including fabrication of cell-encapsulating microscale hydrogels (microgels), self-assembled cell aggregation, generation of cell sheets, and direct printing of cells [183], [184], [185] (Figure 11). These microscale building blocks can be successfully assembled into complex tissue constructs, with control over features such as the shape and composition of individual blocks [186], [187].




Figure 11: Schematic of “top-down” and “bottom-up” approaches for tissue engineering. (A) In the top-down approach, cells are seeded on a biocompatible and biodegradable scaffold and are expected to populate in the scaffold and create their own extracellular matrix. (B) In the bottom-up approach, various methods are utilized for generating tissue building blocks and these units can be engineered into large tissue constructs via multiple assembling methods [188].

2.8.1 Conventional Scaffold Fabrication Techniques

Several techniques have been developed to process synthetic and natural scaffold materials into porous structures. These conventional scaffold fabrication techniques are defined herein as processes that create scaffolds having a continuous, uninterrupted pore structure which lacks any long-range channelling microarchitecture.

Conventional scaffold fabrication techniques include:

- fiber bonding [189] and [190],
- phase separation [191] and [192],
- solvent casting/particulate leaching [193], [194], [195] and [196],
- membrane lamination [197],
- melt molding [198],
- gas foaming/high pressure processing [199] and [200],
- hydrocarbon templating [201],
- freeze drying [202], [203],
- combinations of these techniques (e. g., gas foaming/ particulate leaching [204], etc).

Although conventionally produced scaffolds hold great promise and have been applied to engineer a variety of tissues with varying success, most are limited by some forms of flaws, which restrict their scope of applications.

Table 2: Summarizes the advantages and limitations of these conventional techniques [205].

Technique	Advantages	Limitations
Fiber bonding	Easy process High porosity High surface area to volume ratio	High processing temperature for non-amorphous polymer Limit range of polymers Lack of mechanical strength Problems with residual solvent Lack of control over micro-architecture
Phase separation	Allows incorporation of bioactive agents Highly porous structures	Lack of control over micro-architecture Problems with residual solvent Limited range of pore sizes
Solvent casting and particulate leaching	Highly porous structures Large range of pore sizes Independent control of porosity and pore size Crystallinity can be tailored	Limited membrane thickness Lack of mechanical strength Problems with residual solvent Residual porogens
Membrane lamination	Macro shape control Independent control of porosity and pore size	Lack of mechanical strength Problems with residual solvent Tedious and time-consuming Limited interconnected pores
Melt moulding	Independent control of porosity and pore size Macro shape control	High processing temperature for non-amorphous polymer Residual porogens
Polymer/ceramic fiber composite-foam	Good compressive strength Independent control of porosity and pore size	Problems with residual solvent Residual porogens
High-pressure processing	Organic solvent free Allows incorporation of bioactive agents	Nonporous external surface Closed pore structure
High-pressure processing and particulate leaching	Organic solvent free Allows incorporation of bioactive agents Highly porous structures Large range of pore sizes Independent control of porosity and pore size	Limited interconnected pores Lack of mechanical strength Residual porogens
Freeze drying	Highly porous structures High pore interconnectivity	Limited to small pore sizes
Hydrocarbon templating	No thickness limitation Independent control of porosity and pore size	Problems with residual solvent Residual porogens

2.8.2 Solid Freeform Fabrication Techniques

Solid freeform fabrication (SFF) techniques are computerized fabrication techniques that can rapidly produce highly complex three-dimensional physical objects using data generated by computer-aided design (CAD) systems, computer-based medical imaging modalities, digitizers and other data makers [206]. Unlike conventional computerized machining processes which involve the removal of materials from a stock, SFF techniques use the underlying concept of layered manufacturing [206], [207] whereby three-dimensional objects are fabricated with layer-by-layer building via the processing of solid sheet, liquid or powder material stocks.

Solid freeform fabrication (SFF) may produce scaffolds with customised external shape and predefined and reproducible internal morphology, which not only can control pore size, porosity and pore distribution, but can also make structures to increase the mass transport of oxygen and nutrients throughout the scaffold.

The flexibility and outstanding manufacturing capabilities of SFF have been employed for biomedical applications ranging from the production of scale replicas of human bones [208] and body organs [209] to advanced customized drug delivery devices [210] and other areas of medical sciences including anthropology [211], palaeontology [212] and medical forensics [213].

SFF include:

- three dimensional printing (3DP),
- stereolithography (SLA),
- fused deposition modelling (FDM),
- selective laser sintering (SLS),
- 3D plotter,
- phase-change jet printing [214].

Table 3: Summarizes the capabilities and limitaions of the three solid free-form fabrication techniques [205].

Technique	Build resolution, [mm]	Advantages	Limitations
3D-P	0,100 ± 0,020 Achievable pore size = 45–100 µm	Easy process High porosity High surface area to volume ratio Complete pore interconnectivity Macro shape control Independent control of porosity and pore size Wide range of materials	Use of toxic organic solvents Lack of mechanical strength Limited to small pore sizes
FDM	0,050 ± 0,127 Achievable pore size = 250–1000 µm	High porosity High surface area to volume ratio Complete pore interconnectivity Macro shape control Independent control of porosity and pore size Good compressive strengths Solvent free	High processing temperatures Limited material range Inconsistent pore opening in x-,y- and z-directions Pore occlusion at boundaries Requires support structures for irregular shapes
SLS	0,076 ± 0,250 Achievable pore size = 45–100 µm	High porosity High surface area to volume ratio Complete pore interconnectivity Macro shape control Independent control of porosity and pore size Good compressive strengths Wide range of materials Solvent free	High processing temperatures Limited to small pore sizes

2.8.3 Collagen Scaffold the Most Used Fabrication Techniques

Many extracellular proteins, including collagen, have a nanoscale fibrous structure (50–500 nm in diameter) in vivo which has been found to enhance cell attachment, proliferation, and differentiation [215], [216]. Nanofibrous biomimetic scaffolds consist of biodegradable polymer nanofibers, which can be fabricated by several methods, including electrospinning, phase-separation, and self-assembly, and can mimic the nanofibrillar structure of the extracellular matrix in vivo (Figure 12). In Table 4 are summarized parameters of mentioned methods.




Figure 12: Schematic of current techniques (a) phase separation, (b) self-assembly, and (c) electrospinning to create fibrillar structures in synthetic scaffolds [217].

Table 4: Different methods for fabricating three-dimensional nanostructured scaffolds [188].

Method	Polymer	Diameter of fiber [nm]	Porosity	Cell viability	Material types/ commercially available	Applications for TE
Electro-spinning	PLLA PLGA PGA/PLLA Collagen/PCL Chitosan/PCL Silk/HAP	400–1100	80%–95%	<80%	30/ available	Skin Cartilage Vascular Nerve Bone
Phase-separation	PLLA/HAP PLGA Chitosan	50–500	60%–98%	<98%	15–20/ available	Bone
Freeze-drying	Chitosa/PLLA Collagen/GAG Gelatin-PHEMA	50–450	30%–80%	<90%	15/ available	Tendon Bone/tendon Skin
Self-assembly	Peptide	5–300	80%–90%	60%–95%	5–10/ not known	Cartilage

Here, we focus only on the method we use for fabrication porous collagen sponges – phase separation, especially freeze-drying fabrication method.

2.8.3.1 Phase Separation

The phase separation process can be induced thermally or by a nonsolvent and was developed for the fabrication of 3D porous scaffolds [174], [218], [219]. Induction of the phase separation process using a nonsolvent commonly results in scaffolds with a heterogeneous pore structure which is not suitable for fabrication of tissue engineering

scaffolds, which generally need a uniform pore structure [220]. The thermally induced phase separation process takes place when a homogeneous polymer solution becomes thermodynamically unstable under certain temperature conditions and tends to separate into a multiphase system domains, comprising a polymer-lean phase (with a low polymer concentration) and a polymer-rich phase (with a high polymer concentration) [221], [222]. Subsequently, the polymer-rich phase solidifies to form a matrix while the polymer-lean phase turns into pores as a result of solvent removal. Thermally induced phase separation can be divided into solid-liquid phase separation and liquid-liquid phase separation.

The solid-liquid phase separation process, also called emulsion freeze drying, is used to induce solvent crystallization from a polymer solution by lowering the temperature, which leads to formation of pores after removal of solvent crystals.

Freeze-drying has emerged as a drying process for converting solutions of labile materials into solids of sufficient stability for distribution and storage in applications such as food science, pharmaceuticals, and enzyme stabilization [223], [224], [225]. Freeze-drying involves three major steps: the solution is frozen at a low temperature ($-70\text{ }^{\circ}\text{C}$ to $-80\text{ }^{\circ}\text{C}$); the frozen sample is located in a chamber in which the pressure is lowered (to a few millibars) through a partial vacuum, known as the primary drying process, in which ice in the material is removed by direct sublimation; and most of the unfrozen water in the material is removed by desorption in a secondary drying process.

Porosity and pore diameter in porous scaffolds prepared using the freeze-drying method can be regulated by the freeze-drying pressure [219], (Figure 13). Although there are several advantages of the freeze-drying method, including use of water and ice crystals instead of an organic solvent in the scaffold fabrication process, which is more suitable for biomedical applications, it is still a big challenge to engineer scaffolds with hierarchical structures (e.g. vascularized systems) using this approach.




Figure 13: The schematic diagram of solid-liquid phase separation – freeze-drying technique [226].

In the liquid-liquid phase separation process, polymer solutions with an upper critical temperature form a bicontinuous structure (both polymer-lean phase and polymer-rich phase) [4], [227].

Various synthetic polymeric nanofibers have been fabricated using phase separation methods for tissue engineering applications [171], [172], [192], [228]. Several natural polymers have been fabricated into three-dimensional porous scaffolds, for instance, chitosan scaffolds with nanofibrous or microfibrinous structures prepared by solid-liquid phase separation.

The porosity and fiber size of the scaffolds can be regulated by several methods, including phase separation temperature and polymer concentration [229].

Phase separation holds great potential for fabrication of three-dimensional nanofibrous scaffolds with uniform pore structures through dual or multiple phase separation processes. In addition, phase separation can engineer three-dimensional shapes via several techniques, including solid free-form fabrication, rapid prototyping, and computer-assisted design and manufacture. However, limitations such as limited material selection and inadequate resolution still exist.

2.9 Collagen-Based Scaffolds for Tissue Engineering and Their Application

The material of scaffolds for tissue engineering can be any biomaterial that mimics one or multiple characteristics of the natural ECM [230], but is expected to function as a scaffold to replace natural collagen-based ECM. Much research has been reported on collagen, its denatured forms or collagen-based materials as biomaterials for scaffold fabrication in tissue engineering [231], [232], [233], [234], [235], [236].

2.9.1 Pure Collagen Scaffold

Collagen type I, II and III could form collagen fibers that are similar to or even fully reproduced the structural and biological properties of the natural collagen ECM under optimizing conditions. By electrospinning, collagen type I produced fibers exhibiting the 67 nm D-repeat banding pattern, which is a characteristic of native collagen [237]. Using lyophilization can be determined the collagen concentration in solutions which determines the mechanical properties of the scaffold [238]. Proper concentration could be chosen according to the implant position of the scaffold.

Despite the excellent biological properties of the pure collagen scaffold, it presents poor mechanical properties and structural stability. Physical treatment or chemical agents can be used to achieve intermolecular cross-linking of collagen, thus modifying the properties of the collagen scaffold.

2.9.2 Collagen/Natural Polymer Blend Scaffold

Cross-linking strategies of the pure collagen scaffold enhance the mechanical and structural properties, but may introduce negative effects on cellular response in vivo. Hence, a mixture of natural or synthetic polymers can be used to overcome the limitations of the monocomponent system. Natural polymers (such as chitosan, silk fibroin, hyaluronic acid, alginate, etc.) have been widely used in tissue engineering due to their similar features to native ECM [239].

2.9.3 Collagen/Synthetic Polymer Blend Scaffold

Blending of collagen with synthetic polymers also makes it possible for scaffolds to perform both with optimal mechanical and biological properties in specific engineering applications. In this case, the synthetic polymer undertakes mechanical support to the structure of scaffolds, while collagen on the surface and inside of the scaffolds provides

cell recognition signals, which is crucial for cell behaviors and development [240]. Scaffolds composed of collagen and synthetic polymers, such as poly (ϵ -caprolactone) (PCL), polylactic acid (PLA), poly(ethylene glycol) (PEG), polyglycolide (PGA), poly(lactide-*co*-glycolide) (PLGA) and polyvinyl alcohol (PVA), have been widely used for tissue engineering.

2.9.4 Collagen/Inorganic Hybrid Scaffold

Organic-inorganic composite materials have drawn much attention due to their ability to combine excellent properties of individual constituents. Hybridization can achieve tailor-made performances (such as morphology, stiffness, degradation) and meet various requirements in tissue engineering [241], [242]. Several inorganic materials, such as hydroxyapatite (HA, $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$), silicate and β -tricalcium phosphate (β -TCP, $\text{Ca}_3(\text{PO}_4)_2$), have been used in the construction of tissue engineering scaffolds.

2.9.5 Collagen Scaffold Modified with Growth Factors

Growth factors can regulate a variety of cellular processes; they are intercellular signaling molecules promoting cell migration, proliferation, differentiation and maturation depending on their type [243].

Generally, there is an initial burst release of growth factors encapsulated in the scaffold, which is usually not effective and welcome. Hence, an appropriate loading method is crucial to the stable, sustainable and controllable release of growth factors on the scaffold.

2.9.6 Applications of Collagen-Based Scaffolds in Tissue Engineering

In this section, several typical applications of collagen-based scaffolds in tissue engineering will be introduced, respectively.

2.9.6.1 Nerve Tissue

Collagen-based biomaterials have been extensively studied as a promising nerve guide [244], [245], [246], [247]. Multiple compositions of collagen-based nerve conduits have recently been tested with positive results compared to clinically used autografts. Most collagen nerve guides are engineered from crosslinked collagen solution molded into tubular shape [248]. Pore orientation [249], [250], addition of neurotrophic factors [251], [252] and cell delivery [253], [254], [255] are currently being investigated in an attempt to enhanced nerve guides for clinical applications. Collagen-based biomaterials can also be used to develop innovative three-dimensional tissue-engineered nervous system models to promote 3D axonal migration and myelination of sensory or motor neurons by Schwann cells through a connective tissue [256].

2.9.6.2 Bone/Cartilage Tissue

Bone tissues are mainly composed of collagen type I and HA with a small amount of type V. Hence, collagens blended with nano-inorganic materials are more widely used to prepare scaffolds that mimic natural ECM of bone in bone repair.

Cartilage defects cause joint pain and loss of mobility [257]. Chondrocytes show low rates of regeneration due to their non-mobility and the absence of progenitor cells and vascular networks in the tissue [258]. MSCs have been commonly employed as a main source of seeding cells in cartilage tissue engineering.

2.9.6.3 Tendon/Ligament Tissue

Tendons and ligaments are fibrous connective tissues, with collagen comprising 70 % to 80 % of their dry weight [259]. Both tendon and ligament have weak spontaneous regeneration ability and never totally recover from full-thickness lesions. The substantial donor site morbidity limits autograft applications for injured tissue and encourages the search for alternative solutions. Collagen scaffold provides an excellent way for tendon/ligament repair and regeneration.

2.9.6.4 Vascular Diseases

Two main problems arise in the domain of vascular diseases: cardiovascular malfunction and venous or arterial pathologies such as atherosclerosis. In the case of heart diseases, tissue engineering solutions rely principally on acellular matrix colonization and implantation due to the complex structural architecture of the heart like heart valves [260], [261].

Vascular grafts may induce immediate thrombus after implantation due to their lack of healthy endothelium. Vascular endothelialization can reduce thrombosis, inhibit excessive hyperplasia of intima and significantly improve the long-term patency rate of artificial blood vessels.

Considering the typical requirement of autologous cells, whose amplification in vitro is time consuming, cell-free vascular grafts have gained much attention.

Combining the cell-free vascular graft with endogenous ECs represents a great progress in vascular tissue engineering. Future research directions may be focused on the development of vascular material and immobilization of growth factor.

2.9.6.5 Skin and Cornea

Skin and cornea share a similar tissue structure: dermis and stroma both being connective tissues; epidermis and cornea being stratified epithelia. Collagen-based wound dressings have been applied for decades for burn coverage applications and ulcer treatment [262], [263]. Highly sophisticated and innovative tissue-engineered skin models have been developed with melanocytes [264], a capillarylike network [265], dendritic cells [266], sensory innervation [133], [256], adipose tissue [267], and tissue reproducing psoriatic or sclerotic phenotypes [268], [269].

Mesenchymal stem cell delivery to the wound bed in collagen-based biomaterial is a growing topic in wound healing [267], [270], [271]. The combination of collagenous biomaterials and stem cells could also be a valuable strategy to treat corneal defects. In the last decade, collagen scaffolds have been intensively studied for the delivery of limbal epithelial stem cells to damaged cornea [272], [273], [274], [275], [276], [277]. Advances in collagen-based corneal scaffolds also include the utilization of recombinant human collagen [276], [278], [279], [280], [281], the secretion of collagen by the fibroblasts themselves (self-assembled fibroblasts sheets) [282] and surface modification to reduce extensive endothelialization [283].

Many organic/inorganic materials can be used to strengthen the properties of collagen scaffolds in scientific research, but the materials approved by the U.S. Food and Drug Administration (FDA) for clinical applications are limited. The FDA has approved only collagen, hyaluronic acid, PLLA, HA and non-biodegradable polymethylmethacrylate (PMMA) beads used as dermal fillers since July 2015 [284].

2.9.6.6 Urogenital System

The use of collagen-based biomaterials in the domain of urogenital diseases and dysfunctions rely principally on acellular ECM from either small intestinal submucosa (SIS) or bladder submucosa (BSM) [285], [286]. More recent surgical procedures aiming to solve genitourinary disorders use acellular collagen scaffolds in bladder augmentation [287], [288], [289] and urethral stricture [291], [292], [293].

Collagen-composite scaffolds populated with the patient's own urothelial and muscle cells or self-assembled fibroblast sheets are also a promising strategy for bladder augmentation [294], [295], [296]. Vesico-urethral reflux and incontinence are other defects of the urogenital system which can also be solved using injection of collagen biomaterials [297], [298], [299].

2.9.6.7 Dermal Filler, Wound Dressing and Delivery Systems

FDA approved dermal filler commonly used in facial rejuvenation or reconstructive surgery is using collagen from three distinct sources: Bovine Zyderm®, porcine Evolence™, human CosmoDerm® and Cymetra® [300], [301]. Although other collagen-based biomaterials are available for this purpose [302], these products can be useful for medical office-based interventions.

Wound dressings that are also delivery systems represent an interesting application for collagenbased applications.

The delivery properties of collagen-based biomaterials also display great potential for ulcer treatment [250]; abdominal wall defect reconstruction [303], [304], [305]; implants delivering antibiotics [306], [307], [308], [309]; gene therapy delivered by collagen matrix [310].

Collagen scaffolds have also shown to accurately deliver cells, proteins, drugs and nucleic acids on a predictable and long-term basis [311], [312], [313], [314]. The biodegradability of collagen and its low immunogenicity make it a substrate of choice for internal and topical pharmacogenomical applications.

3 EXPERIMENTAL PART

Purpose of experimental part was to prepare 3D porous collagen scaffolds by freeze-drying and their modification with bioactive compounds, as well as observe the influence of biologically active additives, crosslinking agents, and enrichment with growth factors on the properties of the prepared scaffolds and their bioactivity in tissues of living organisms. For the characterization, morphological properties, structure, porosity, swelling stability, chemical composition and biological properties were observed.

The experimental part is secret for the protection of intellectual property.

3.1 Chemicals

3.2 Equipments

3.3 Preparation of Chitin/Chitosan-Glucan Complex

3.4 Preparation of Samples

3.4.1 Collagen Sponges

3.4.2 Collagen Sponges with CaOC

3.4.3 Collagen Sponges with Chitosan

3.4.4 Collagen Sponges with Complex

3.4.5 Crosslinking of Collagen Sponges with Carbodiimides

3.4.6 Sponges Enriched with PRP

3.5 Characterization of the samples

3.5.1 Morphology and Porosity

3.5.2 Swelling Ratio and Water Content

3.5.3 Degradation

3.5.4 Fourier Transformed-Infrared Spectroscopy

3.5.5 Differential Scanning Calorimetry

3.5.6 Biological Properties

4 RESULT AND DISCUSSION

4.1.1 Morphology and Porosity

4.1.2 Swelling Ratio and Water Content

4.1.3 Degradation

4.1.4 Fourier Transformed-Infrared Spectroscopy

4.1.5 Differential Scanning Calorimetry

4.1.6 Biological Properties

5 CONCLUSION

6 REFERENCES

- [1] GLOTZBACH, Jason P., Victor W. WONG, Geoffrey C. GURTNER a Michael T. LONGAKER. Regenerative Medicine. *Current Problems in Surgery*. 2011, **48**(3), 148–212.
- [2] GAGE, F. H. Cell therapy. *Nature: the international weekly journal of science*. London: Nature Publishing Group. 1998, 392(6679), 18–24.
- [3] MATSUURA, Katsuhisa, Rie UTOH, Kenichi NAGASE, Teruo OKANO, Gadi PELLER a Dan GAZIT. Cell sheet approach for tissue engineering and regenerative medicine. *Journal of Controlled Release*. 2014, 190(7–8), 228–239.
- [4] O'BRIEN, Fergal J., Cong CHEN, Yingjun WANG, Xiaofeng CHEN a Chang DU. Biomaterials: A Review. *Materials Today*. 2011, **14**(3), 88–95.
- [5] PAOLO BIANCO a PAMELA GEHRON ROBEY. Stem cells in tissue engineering. *Nature* [online]. Nature Publishing Group. 2001, 414(6859), 118 [cit. 2015-12-09].
- [6] QUAGLIA, Fabiana, Pamela Gehron ROBEY, Geoffrey C. GURTNER a Michael T. LONGAKER. Bioinspired tissue engineering: The great promise of protein delivery technologies. *International Journal of Pharmaceutics*. 2008, 364(2), 281–297.
- [7] ZHAO, Dapeng, Lei LEI, Shuo WANG a Hemin NIE. Understanding cell homing-based tissue regeneration from the perspective of materials. *J. Mater. Chem. B*. 2015, **3**(37), 7319–7333.
- [8] ALISON, MR, S ISLAM a Megana K. PRASAD. Attributes of adult stem cells. *The Journal of Pathology*. 2009, 217(2), 144–160.
- [9] KØRBLING, Martin a ZeeFv ESTROV. Adult stem cells for tissue repair – a new therapeutic concept? *The New England journal of medicine* [online]. 2003, 349(6), 570 [cit. 2015-12-10].
- [10] S. BAJADA, I. MAZAKOVA, B. A. ASHTON, J. B. RICHARDSON, N. ASHAMMAK. Stem Cells in Regenerative Medicine. In: N. Ashammakhi, R. Reis, F. Chiellini (eds). *Topics in Tissue Engineering*. 2008, 4, 1–28.
- [11] TAKAHASHI, Kazutoshi a Shinya YAMANAKA. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell*. 2006, 126(4), 663–676.
- [12] Biology Notes: Developmental Biology Articles – Adult stem cells. *Fastbleep Ltd.* [online]. 2016 [cit. 2016-02-03]. Accessible from URL: <http://www.fastbleep.com/biology-notes/32/158/852>
- [13] KOH, Chester J a Anthony ATALA. Tissue engineering, stem cells, and cloning: opportunities for regenerative medicine. *Journal of the American Society of Nephrology: JASN* [online]. 0040n. 1., 15(5), 1113 [cit. 2015-12-10]. ISSN 1046-6673.
- [14] GEARHART, John, Evanthia E. PASHOS a Megana K. PRASAD. Pluripotency Redux — Advances in Stem-Cell Research. *New England Journal of Medicine*. 2007, 357(15), 1469–1472.
- [15] CHEN, Fa-Ming a Yan JIN. Periodontal Tissue Engineering and Regeneration: Current Approaches and Expanding Opportunities. *Tissue Engineering Part B: Reviews*. 2010, 16(2), 219–255.

- [16] KOBASA, Serge a W Mark SALTZMAN. Bioengineering Approaches to Controlled Protein Delivery: Current Approaches and Expanding Opportunities. *Pediatric Research*. 2008, 63(5), 513–519.
- [17] VASITA, Rajesh a Dhirendra S KATTI. Growth factor-delivery systems for tissue engineering: a materials perspective. *Expert Review of Medical Devices*. 2006, 3(1), 29–47.
- [18] VARKEY, Mathew, Sebastien A GITTENS a Hasan ULUDAG. Growth factor delivery for bone tissue repair: an update. *Expert Opinion on Drug Delivery*. 2004, 1(1), 19–36.
- [19] ANDREADIS, Stelios T., David J. GEER a Hasan ULUDAG. Biomimetic approaches to protein and gene delivery for tissue regeneration: an update. *Trends in Biotechnology*. 2006, 24(7), 331–337.
- [20] BALASUBRAMANIAN, V, Ozana ONACA, Ramona ENEA, David W HUGHES a Cornelia G PALIVAN. Protein delivery: from conventional drug delivery carriers to polymeric nanoreactors. *Expert Opinion on Drug Delivery*. 2010, 7(1), 63–78.
- [21] CHEN, Fa-Ming, Richard M. SHELTON, Yan JIN, Iain L.C. CHAPPLE a Cornelia G PALIVAN. Localized delivery of growth factors for periodontal tissue regeneration: Role, strategies, and perspectives. *Medicinal Research Reviews*. 2009, 29(3), 472–513.
- [22] GULDBERG, Robert E, Richard M. SHELTON, Yan JIN, Iain L.C. CHAPPLE a Cornelia G PALIVAN. Spatiotemporal Delivery Strategies for Promoting Musculoskeletal Tissue Regeneration: Role, strategies, and perspectives. *Journal of Bone and Mineral Research*. 2009, 24(9), 1507–1511.
- [23] TAYALIA, Prakriti, David J. MOONEY, Yan JIN, Iain L.C. CHAPPLE a Cornelia G PALIVAN. Controlled Growth Factor Delivery for Tissue Engineering: Role, strategies, and perspectives. *Advanced Materials*. 2009, 21(32–33), 3269–3285.
- [24] LANGER, Robert. Drug delivery and targeting. *Nature* [online]. London: Nature Publishing Group, 1998, 392(6679), 5–10 [cit. 2016-02-05].
- [25] TABATA, Yasuhiko, David J. MOONEY, Yan JIN, Iain L.C. CHAPPLE a Cornelia G PALIVAN. Regenerative inductive therapy based on DDS technology of protein and gene: Role, strategies, and perspectives. *Journal of Drug Targeting*. 2015, 14(7), 483–495.
- [26] BIONDI, Marco, Francesca UNGARO, Fabiana QUAGLIA, Paolo Antonio NETTI a Cornelia G PALIVAN. Controlled drug delivery in tissue engineering: Role, strategies, and perspectives. *Advanced Drug Delivery Reviews*. 2008, 60(2), 229–242.
- [27] INTINI, Giuseppe. The use of platelet-rich plasma in bone reconstruction therapy. *Biomaterials*. 2009, 30(28), 4956–4966.
- [28] ANITUA, Eduardo, Isabel ANDIA, Bruno ARDANZA, Paquita NURDEN a Alan T NURDEN. Autologous platelets as a source of proteins for healing and tissue regeneration. *Thrombosis and Haemostasis*. 2004.
- [29] MARX, Robert E., Isabel ANDIA, Bruno ARDANZA, Paquita NURDEN a Alan T NURDEN. Platelet-Rich Plasma (PRP): What Is PRP and What Is Not PRP? *Implant Dentistry*. 2001, 10(4), 225–228.
- [30] MARX, Robert E, Isabel ANDIA, Bruno ARDANZA, Paquita NURDEN a Alan T NURDEN. Platelet-rich plasma: evidence to support its use. *Journal of Oral and Maxillofacial Surgery*. 2004, 62(4), 489–496.

- [31] MISHRA, Allan. Platelet-Rich Plasma. *Orthopedics*. 2010, 33(7): 486–487.
- [32] FUFU, Duretti, Blake SHEALY, May JACOBSON, Sherwin KEVY a Martha M. MURRAY. Activation of Platelet-Rich Plasma Using Soluble Type I Collagen: evidence to support its use. *Journal of Oral and Maxillofacial Surgery*. 2008, 66(4), 684–690.
- [33] EPPLEY, Barry L., Jennifer E. WOODDELL, Joel HIGGINS, Sherwin KEVY a Martha M. MURRAY. Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound Healing. *Plastic and Reconstructive Surgery*. 2008, 66(4), 1502–1508.
- [34] SCHLIEPHAKE, H., Jennifer E. WOODDELL, Joel HIGGINS, Sherwin KEVY a Martha M. MURRAY. Bone growth factors in maxillofacial skeletal reconstruction: Implications for Wound Healing. *International Journal of Oral and Maxillofacial Surgery*. 2002, 31(5), 469–484.
- [35] JAMESON, Carol A., Jennifer E. WOODDELL, Joel HIGGINS, Sherwin KEVY a Martha M. MURRAY. Autologous Platelet Concentrate for the Production of Platelet Gel: Implications for Wound Healing. *Laboratory Medicine*. 2007, 38(1), 39–42.
- [36] WROBLEWSKI, Andrew P., Hector A. MEJIA, Vonda J. WRIGHT, A. NOBLE a K. WILLETT. Application of Platelet-Rich Plasma to Enhance Tissue Repair: A REVIEW OF THE LITERATURE. *Operative Techniques in Orthopaedics*. 2010, 20(2), 98–105.
- [37] BASU, Debdatta, Rajendra KULKARNI a Tomas ALBREKTSSON. Overview of blood components and their preparation: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Indian Journal of Anaesthesia*. 2014, **58**(5), 529.
- [38] ARMSTRONG, Beryl, Rajendra KULKARNI a Tomas ALBREKTSSON. Introduction to Blood Transfusion Technology: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *ISBT Science Series*. 2008, **3**(2), x-x.
- [39] DOHAN EHRENFEST, David M., Lars RASMUSSEN, Tomas ALBREKTSSON, Marilde BARONE, Marco GUIZZARDI, Barbara CAMPANATI, Marco MORONI a Angelo CARABELLI. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends in Biotechnology*. 2009, 27(3), 158–167.
- [40] WEIBRICH, Gernot, Wilfried K.G. KLEIS, Gerd HAFNER, W.E. HITZLER a Wilfried WAGNER. Comparison of platelet, leukocyte, and growth factor levels in point-of-care platelet-enriched plasma, prepared using a modified Curasan kit, with preparations received from a local blood bank: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Clinical Oral Implants Research*. 2003, 14(3), 357–362.
- [41] MAZZUCCO, Laura, Piero BORZINI, Rajalakshmi GOPE, A. NOBLE a K. WILLETT. Platelet-Derived Factors Involved in Tissue Repair—From Signal to Function: What Is PRP and What Is Not PRP? *Transfusion Medicine Reviews*. 2010, 24(3), 218–234.
- [42] BORZINI, Piero a Laura MAZZUCCO. Platelet gels and releasates. *Curr. Opin. Hematol*. 2005, 12(6), 473–479.
- [43] CROVETTI, Giovanni, Giovanna MARTINELLI, Marwan ISSI, Marilde BARONE, Marco GUIZZARDI, Barbara CAMPANATI, Marco MORONI

- a Angelo CARABELLI. Platelet gel for healing cutaneous chronic wounds. *Transfusion and Apheresis Science*. 2004, 30(2), 145–151.
- [44] MAZZUCCO, Laura, Dante MEDICI, Massimo SERRA, et al. The use of autologous platelet gel to treat difficult-to-heal wounds: a pilot study. *Transfusion*. 2004, 44(7), 1013–1018.
- [45] OGINO, Yoichiro, Yasunori AYUKAWA, Toshio KUKITA, et al. The contribution of platelet-derived growth factor, transforming growth factor- β 1, and insulin-like growth factor-I in platelet-rich plasma to the proliferation of osteoblast-like cells: a pilot study. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*. 2006, 101(6), 724–729.
- [46] DOUCET, Christelle, Isabelle ERNOU, Yizhou ZHANG, et al. Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications. *Journal of Cellular Physiology*. 2005, 205(2), 228–236.
- [47] RANZATO, Elia, Simona MARTINOTTI, Andrea VOLANTE, et al. Platelet lysate modulates MMP-2 and MMP-9 expression, matrix deposition and cell-to-matrix adhesion in keratinocytes and fibroblasts: A safety substitute for animal serum in cell-based therapy applications. *Experimental Dermatology*. 2011, 20(4), 308–313.
- [48] DEL FANTE, Claudia, Cesare PEROTTI, Maria Cristina BONFERONI, et al. Platelet Lysate Mucohesive Formulation to Treat Oral Mucositis in Graft Versus Host Disease Patients: A New Therapeutic Approach. *AAPS PharmSciTech*. 2011, 12(3), 893–899.
- [49] SANDRI, Giuseppina, Maria Cristina BONFERONI, Silvia ROSSI, et al. Platelet lysate formulations based on mucoadhesive polymers for the treatment of corneal lesions: A New Therapeutic Approach. *Journal of Pharmacy and Pharmacology*. 2011, 63(2), 189–198.
- [50] SANDRI, Giuseppina, Maria Cristina BONFERONI, Franca FERRARI, et al. An In Situ Gelling Buccal Spray Containing Platelet Lysate for the Treatment of Oral Mucositis: A New Therapeutic Approach. *Current Drug Discovery Technologies*. 2011, 8(3), 277–285.
- [51] SANDRI, Giuseppina, Maria Cristina BONFERONI, Silvia ROSSI, et al. Thermosensitive eyedrops containing platelet lysate for the treatment of corneal ulcers: A New Therapeutic Approach. *International Journal of Pharmaceutics*. 2012, 426(1–2), 1–6.
- [52] ROSSI, Silvia, Franca FERRARI, Maria Cristina BONFERONI, et al. Comparison of poloxamer- and chitosan-based thermally sensitive gels for the treatment of vaginal mucositis: A New Therapeutic Approach. *Drug Development and Industrial Pharmacy*. 2014, 40(3), 352–360.
- [53] LYONS F., PARTAP S., O'BRIEN F. J. Part 1: scaffolds and surfaces. *Technol Health Care*. 2008, 16, 305–17.
- [54] MALLICK, Kajal. Biomaterial scaffolds for tissue engineering. *Frontiers in Bioscience*. 2013, **E5**(1), 341.
- [55] OH, Hwan Hee, Young-gwang KO, Hongxu LU, Naoki KAWAZOE a Guoping CHEN. Preparation of Porous Collagen Scaffolds with Micropatterned Structures. *Advanced Materials* [online]. Weinheim: WILEY-VCH Verlag, 2012, 24(31), 4311–4316 [cit. 2016-04-28].

- [56] MARTIN, Ivan, David WENDT a Michael HEBERER. The role of bioreactors in tissue engineering. Trends in Biotechnology [online]. 2004, 22(2), 80–86 [cit. 2016-04-28].
- [57] SOKOLSKY-PAPKOV, Marina, Kapil AGASHI, Andrew OLAYE, Kevin SHAKESHEFF a Abraham J. DOMB. Polymer carriers for drug delivery in tissue engineering. Advanced Drug Delivery Reviews [online]. 2007, 59(4), 187–206 [cit. 2016-04-28].
- [58] HUTMACHER, Dietmar W. Scaffolds in tissue engineering bone and cartilage. Biomaterials [online]. 2000, 21(24), 2529–2543 [cit. 2016-04-28].
- [59] DRURY J. L., MOONEY D. J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials. 2003, 24, 4337–51.
- [60] TABATA Y., HIJIKATA S., MUNIRUZZAMAN M., IKADA Y. Neovascularization effect of biodegradable gelatin microspheres incorporating basic fibroblast growth factor. J Biomater Sci Polym Ed. 1999, 10, 79–94.
- [61] MAYET. Naeema. Yahya E. CHOONARA. Pradeep KUMAR. Lomas K. TOMAR. Charu TYAGI. Lisa C. DU TOIT a Viness PILLAY. A Comprehensive Review of Advanced Biopolymeric Wound Healing Systems. Journal of Pharmaceutical Sciences. 2014. 103(8). 2211–2230.
- [62] HOFFMAN, Allan S., Lonnie D. SHEA, Elizabeth SMILEY a Jeffrey BONADIO. Hydrogels for Biomedical Applications. Advanced Drug Delivery Reviews [online]. 2002, 43, 3–12 [cit. 2016-04-28].
- [63] DRURY, Jeanie L., David J. MOONEY, Pradeep KUMAR, Lomas K. TOMAR, Charu TYAGI, Lisa C. DU TOIT a Viness PILLAY. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials. 2003, 24(24), 4337–4351.
- [64] CHUNG H. J., PARK T. G. Surface engineered and drug releasing pre-fabricated scaffolds for tissue engineering. Advanced Drug Delivery Reviews . 2007, 9, 249–59.
- [65] WIDMER M. S., MIKOS A. G. Fabrication of biodegradable polymer scaffolds. In: Patrick CW Jr, Mikos AG, McIntire LV, eds. Frontiers in Tissue Engineering; 1998, 107–20.
- [66] PETER, S. J., MILLER M. J., YASKO A. W., YASZEMSKI M. J., MIKOS A. G. Polymer concepts in tissue engineering. J Biomed Mater Res. 1998, 43, 422–7.
- [67] BAILEY, A. J.; Collagen – Nature's framework in the medical, food and leather industries. J Soc. Leather Tech. Chem. 1992, 76, 111–128.
- [68] KHANG G., LEE S.J., KIM M. S., LEE H. B. Biomaterials: tissue engineering and scaffold. In Webster J. (ed.). Encyclopedia of Medical Devices and Instrumentation. 2006, 2, 366–83.
- [69] BABENSEE J. E., MIKOS A. G., ANDERSON J. M., McINTIRE L. V. Host response to tissue engineered devices. Advanced Drug Delivery Reviews. 1998, 33, 111–39.
- [70] KARANDE S. T., AGRAWAL M. C. Functions and requirement of synthetic scaffolds in tissue engineering. In: Laurencin CT, Nair LS (eds.). Nanotechnology and Tissue Engineering: The Scaffolds; 2008, 53.
- [71] FERGAL J. O'Brien. Biomaterials and Scaffolds for Tissue Engineering. Materialstoday Elsevier Ltd. 2011, 14, 88–96.

- [72] CHEUNG, Hoi-Yan, Kin-Tak LAU, Tung-Po LU a David HUI. A critical review on polymer-based bio-engineered materials for scaffold development. *Composites Part B: Engineering*. 2007, 38(3): 291–300.
- [73] SALTZMAN W. M., BALDWIN S. P. Materials for protein delivery in tissue engineering. *Adv Drug Deliv Rev*. 1998, 33, 71–86.
- [74] PETERSEN N., GATENHOLM P. Bacterial cellulose-based materials and medical devices: current state and perspectives. *Appl Microbiol Biotechnol*. 2011, 91, 1277–1286.
- [75] KUMAR V., YANG D. $\text{HNO}_3/\text{H}_3\text{PO}_4\text{-NANO}_2$ mediated oxidation of cellulose-preparation and characterization of bioabsorbable oxidized celluloses in high yields and with different levels of oxidation. *Carbohydr Polym*. 2002, 48, 403–412.
- [76] ZIMNITSKY D. S., YURKSHTOVICH T. L., BYCHOKOVSKY P. M.. Synthesis and characterization of oxidized cellulose. *J Polym Sci A Polym Chem*. 2004, 42, 4785–4791.
- [77] SAITO T., KIMURA S., NISHIYAMA Y., ISOGAI A.. Cellulose nanofibers prepared by TEMPO-mediated oxidation of native cellulose. *Biomacromolecules*. 2007, 8, 2485–2491.
- [78] CAMY S., MONTANARI S., RATTAZ A., VIGNON M., CONDORET J. S.. Oxidation of cellulose in pressurized carbon dioxide. *J Supercrit Fluids*. 2009, 51, 188–196.
- [79] DIMITRIJEVICH S. D., TATARKO M., GRACY R. W., LINSKY C. B., OLSEN C.. Biodegradation of oxidized regenerated cellulose. *Carbohydr Res*. 1990, 195, 247–256.
- [80] ZIMNITSKY D. S., YURKSHTOVICH T. L., BYCHOKOVSKY P. M.. Adsorption of zwitterionic drugs onto oxidized cellulose. *J Colloid Interface Sci*. 2006, 295, 33–40.
- [81] VYTRASOVA J., TYLSOVA A., BROZKOVA I., CERVENKA L., PEJCHALOVA M., HAVELKA P.. Antimicrobial effect of oxidized cellulose salts. *J Ind Microbiol Biotechnol*. 2008, 35, 1247–1252.
- [82] MASOVA L., RYSAVA J., KRIZOVA P., SUTTNAR J., SALAJ P., DYR J. E., HOMOLA J., DOSTALEK J., MYSKA K., PECKA M.. Hemostyptic effect of oxidized cellulose on blood platelets. *Sb Lek*. 2003, 104, 231–236.
- [83] SHANMUGASUNDARAM N., RAVICHANDRAN P., NEELAKANTA R. P., RAMAMURTY N., SUBRATA P., PANDURANGA R. K. Collagen chitosan polymeric scaffolds for the in vitro culture of human epidermoid carcinoma cells. *Biomaterials* 2001, 22(14), 1943–1951.
- [84] YIN, Anlin, Kuihua ZHANG, Michael J. MCCLURE, et al. Electrospinning collagen/chitosan/poly(L -lactic acid- co - ϵ -caprolactone) to form a vascular graft: Mechanical and biological characterization. 2013, 101(5), 1292–301.
- [85] Yong-Woo CHO, Yong-Nam CHO, Sang-Hun CHUNG, Gyeol YOO, Sohk-Won KO. Water-soluble chitin as a wound healing accelerator. *Biomaterials*. 1999, 20, 2139–45.
- [86] MA, L., et al. Collagen/chitosan porous scaffolds with improved biostability for skin tissue engineering. *Biomaterials*. 2003, 24(26), 4833–4841.
- [87] CHEN, Fa-Ming, Min ZHANG a Zhi-Fen WU. Toward delivery of multiple growth factors in tissue engineering: A Review of the Science and Possible Clinical Applications. *Biomaterials*. 2010, 31(24), 6279–6308.

- [88] Hench, L.L., Bioceramics. *Journal of the American Ceramic Society*. 1998, 81 (7), 1705–1727.
- [89] AMBROSIO, A. M. A., SAHOTA, J. S., KHAN, Y. and LAURENCIN, C. T. A novel amorphous calcium phosphate polymer ceramic for bone repair: I. Synthesis and characterization. *J. Biomed. Mater. Res.*, 2001, 58, 295–301. DOI: 10.1002/1097-4636(2001)58:3<295::AID-JBM1020>3.0.CO;2-8
- [90] O'BRIEN, F. J., et al.. A collagen/hydroxyapatite composite scaffold and process for the production thereof. WO2008096334. 2008.
- [91] Gráinne M. CUNNIFFE, Glenn R. DICKSON, Sonia PARTAP. Development and characterisation of a collagen nano-hydroxyapatite composite scaffold for bone tissue engineering. *Journal of Materials Science: Materials in Medicine*. 2010, 21(8), 2293.
- [92] GELSE, K., Lonnie D. SHEA, Elizabeth SMILEY and Jeffrey BONADIO. Collagens—structure, function, and biosynthesis. *Advanced Drug Delivery Reviews* [online]. 2003, 55 (12), 1531–1546 [cit. 2016-04-28].
- [93] NAIR R., SEVUKARAJAN M., MOHAMMED T., BADIVADDIN C. K., KUMAR A. Collagen based drug delivery systems: A Review. *J Innov Trends Pharm Sci*. 2010, 1, 288–304.
- [94] PROCKOP, D. J., KIVIRIKKO, K. I. Collagens: Molecular biology, diseases, and potentials for therapy. *Annu Rev Biochem* 1995, 64, 403–434.
- [95] VAN DER REST, M., GARRONE, R. Collagen family of proteins. *FASEB J*. 1991, 5, 2814–2823.
- [96] FRIESS, Wolfgang. Collagen – biomaterial for drug delivery1Dedicated to Professor Dr. Eberhard Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg, on the occasion of his 70th birthday.1. *European Journal of Pharmaceutics and Biopharmaceutics*. 1998, 45(2): 113–136.
- [97] K. A. PIEZ. Molecular and aggregate structures of the collagens, in: K.A. Piez, A.H. Reddi (Eds.), *Extracellular Matrix Biochemistry*, Elsevier, New York, 1984, 1–40.
- [98] E. J. KUCHARZ. The Collagens: Biochemistry and Pathophysiology, Springer-Verlag, Berlin, 1992, 7–29.
- [99] M. E. NIMNI, R. D. HARKNESS. Molecular structures and functions of collagen, in: M. E. Nimni (Ed.), *Collagen Vol. I – Biochemistry*, CRC Press, Boca Raton, FL, 1988, 1–79.
- [100] SHOULDERS, Matthew D. and Ronald T. RAINES. Collagen Structure and Stability. *Annual Review of Biochemistry*. 2009, 78(1), 929–958.
- [101] ALBERTS, Bruce. *Molecular biology of the cell*. 4th ed. New York: Garland Science, c2002. ISBN 0815332181. ISSN 0-8153-4072-9.
- [102] M. YAMAUCHI, G. Mechanic Crosslinking of collagen, in: M.E. Nimni (Ed.), *Collagen Vol. I – Biochemistry*, CRC Press, Boca Raton, F., 1988, 1, 157–172
- [103] K. REISER, R. J. McCORMICK, R. B. RUCKER, Enzymatic and nonenzymatic cross-linking of collagen and elastin, *FASEB J*. 1992, 6, 2439–2449.
- [104] L. GRAHAM, P. M. GALLOP. Covalent protein crosslinks: general detection, quantitation, and characterization via modification with diphenylborinic acid, *Anal. Biochem*. 1994, 217, 298–305.

- [105] H. PALOKANGAS, V. KOVANEN, A. DUNCAN, S. P. ROBINS. Age-related changes in the concentration of hydroxypyridinium crosslinks in functionally different skeletal muscles, *Matrix*. 1992, 12, 291–296.
- [106] T. E. CAWSTON, G. MURPHY. Mammalian collagenases, in: L. Lorand (Ed.), *Methods in Enzymology, Proteolytic Enzymes*, Academic Press, London, 1981, 80, 711–722.
- [107] D. J. ETHERINGTON, D. PUGH, I. A. SILVER. Collagen degradation in an experimental inflammatory lesion: studies on the role of the macrophage, *Acta Biol. Med. Germ.* 1981, 40, 1625–1636.
- [108] J. A. HUNT, J. S. VAN DER LAAN, J. SCHAKENRAAD, D. F. WILLIAMS. Quantitative in vivo assessment of the tissue response to dermal sheep collagen in abdominal wall defects. *Biomaterials*. 1993, 15, 378–382.
- [109] T. OKADA, T. HAYASHI, Y. IKADA. Degradation of collagen suture in vitro and in vivo, *Biomaterials*. 1992, 13, 448–454.
- [110] T. R. KNAPP, E. LUCK, J. R. DANIELS. Behaviour of solubilised collagen as a bioimplant, *J. Surg. Res.* 1977, 23, 96–105.
- [111] K. R. MEADE, F. H. SILVER. Immunogenicity of collagenous implants, *Biomaterials*. 1990, 11, 176–180.
- [112] K. A. PIEZ, Molecular and aggregate structures of the collagens, in: K.A. Piez, A.H. Reddi (Eds.), *Extracellular Matrix Biochemistry*, Elsevier, New York, 1984, 1–40.
- [113] U. TAKEDA, M. ODAKI, M. YOKATA, Acute and subacute toxicity studies on collagen wound dressing (CAS) in mice and rats, *J. Toxicol. Sci.* 1982, 7(2), 63–91.
- [114] S. D. GORHAM. Collagen, in: D. Byrom (Ed.), *Biomaterials*, Stockton Press, New York, 1991, pp. 55–122.
- [115] A. M. FIELDING. Preparation of neutral salt soluble collagen, in: D.A. Hall (Ed.), *The Methodology of Connective Tissue Research*, Joynson–Bruvvers, Oxford, 1976, 9–12.
- [116] R. L. TRELSTAD. Immunology of collagens, in: H. Furthmayer (Ed.), *Immunochemistry of the Extracellular Matrix, Vol. I Methods*, CRC Press, Boca Raton, FL, 1982, 32–39.
- [117] M. P. SINGH, J. STEFKO, J. A. LUMPKIN, J. ROSENBLATT. The effect of electrostatic charge interactions on release rates of gentamicin from collagen matrices, *Pharm. Res.* 1995, 12, 1205–1210.
- [118] S. SRIVASTAVA, S. D. GORHAM, J. M. COURTNEY. The attachment and growth of an established cell line on collagen, chemically modified collagen, and collagen composite surfaces, *Biomaterials*. 1990, 11, 162–168.
- [119] C. L. WANG, T. MIYATA, B. WEKSLER, A. L. RUBIN, K. H. STENZEL. Collagen-induced platelet aggregation and release. I. Effects of side-chain modifications and role of arginyl residues, *Biochem. Biophys. Acta*. 1978, 544, 555–567.
- [120] K. Panduranga RAO. Recent developments of collagen-based materials for medical applications and drug delivery systems, *J. Biomater. Sci. Polymer Ed.* 1995, 7, 623–645.
- [121] HAUGH M. G., JAASMA M. J., O'BRIEN F. J.. The effect of dehydrothermal treatment on the mechanical and structural properties of collagen-GAG scaffolds. *J Biomed Mater Res A*. 2009, 89, 363–369.

- [122] KEOGH, Michael B., Fergal J. O'BRIEN, Jacqueline S. DALY, et al. Substrate stiffness and contractile behaviour modulate the functional maturation of osteoblasts on a collagen–GAG scaffold: Mechanical and biological characterization. 2010, 6(11), 4305–4313.
- [123] SHAHABEDDIN, L., F. BERTHOD, O. DAMOUR a C. COLLOMBEL. Characterization of Skin Reconstructed on a Chitosan-Cross-Linked Collagen-Glycosaminoglycan Matrix. *Skin Pharmacol.* 1990, **3**(2), 107–114.
- [124] BERTHOD, F., G. SAINTIGNY, F. CHRETIEN, D. HAYEK, C. COLLOMBEL a O. DAMOUR. Optimization of thickness, pore size and mechanical properties of a biomaterial designed for deep burn coverage. *Clinical Materials.* 1994, **15**(4), 259–265.
- [125] BERTHOD, François, Dany HAYEK, Odile DAMOUR, Christian COLLOMBEL, C. COLLOMBEL a O. DAMOUR. Collagen synthesis by fibroblasts cultured within a collagen sponge. *Biomaterials.* 1993, **14**(10), 749–754.
- [126] GARCIA, Yolanda, Naik HEMANTKUMAR, Russell COLLIGHAN, Martin GRIFFIN, Jose Carlos RODRIGUEZ-CABELLO a Abhay PANDIT. In Vitro Characterization of a Collagen Scaffold Enzymatically Cross-Linked with a Tailored Elastin-like Polymer. *Tissue Engineering Part A.* 2009, **15**(4), 887–899.
- [127] YUNG, C.W., L.Q. WU, J.A. TULLMAN, G.F. PAYNE, W.E. BENTLEY a T.A. BARBARI. Transglutaminase crosslinked gelatin as a tissue engineering scaffold. *Journal of Biomedical Materials Research Part A.* 2007, **83A**(4), 1039–1046.
- [128] KHEW, Shih Tak, Qing Jun YANG, Yen Wah TONG, G.F. PAYNE, W.E. BENTLEY a T.A. BARBARI. Enzymatically crosslinked collagen-mimetic dendrimers that promote integrin-targeted cell adhesion. *Biomaterials.* 2008, **29**(20), 3034–3045.
- [129] YEO, T-K., L. BROWN a H. F. DVORAK. Alterations in Proteoglycan Synthesis Common to Healing Wounds and Tumors. *American Journal of Pathology.* 1991, **138**(6), 1437–1450.
- [130] TETI, A. Regulation of cellular functions by extracellular matrix. *Journal of the American Society of Nephrology: JASN* [online]. 9920, **2**(10 Suppl), S83 [cit. 2016-02-21]. ISSN 1046–6673.
- [131] HUANG-LEE, Lynn L. H., Julia H. WU a Marcel E. NIMNI. Effects of hyaluronan on collagen fibrillar matrix contraction by fibroblasts. *Journal of Biomedical Materials Research.* 1994, **28**(1), 123–132.
- [132] ZHONG, Shaoping, Lin Yue Lanry YUNG a Marcel E. NIMNI. Enhanced biological stability of collagen with incorporation of PAMAM dendrimer. *Journal of Biomedical Materials Research Part A.* 2009, **91A**(1), 114–122.
- [133] CAISSIE, René, Marie GINGRAS, Marie-France CHAMPIGNY a François BERTHOD. In vivo enhancement of sensory perception recovery in a tissue-engineered skin enriched with laminin. *Biomaterials.* 2006, **27**(15), 2988–2993.
- [134] ANTONICELLI, Frank, Georges BELLON, Sandrine LORIMIE R., William HORNEBECK. Role of the elastin receptor complex (S-Gal/Cath-A/Neu-1) in skin repair and regeneration. *Wound Repair and Regeneration.* 2009, **17**(5), 631–638.
- [135] SUH, Hwal, Jong Eun LEE, Sandrine LORIMIER a William HORNEBECK. Behavior of Fibroblasts on a Porous Hyaluronic Acid Incorporated Collagen Matrix. *Yonsei Medical Journal.* 2002, **43**(2), 193–.

- [136] E. KHOR. Methods for the treatment of collagenous tissues for bioprostheses, *Biomaterials*. 1997, 18, 95–105.
- [137] K. S. WEADOCK, E. J. MILLER, L. D. BELLINCAMPI, J. P. ZAWADSKY, M. G. DUNN. Physical crosslinking of collagen fibers: comparison of ultraviolet irradiation and dehydrothermal treatment, *J. Biomed. Mater. Res.* 1995, 29, 1373–1379.
- [138] I. V. YANNAS, A. V. TOBOLKSY. Crosslinking of gelatin by dehydration, *Nature*. 1967, 215, 509–510.
- [139] K. WEADOCK, R. M. OLSON, F. H. SILVER. Evaluation of collagen crosslinking techniques, *Biomater. Med. Dev. Artif. Organs*. 1984, 11, 293–318.
- [140] K. S. WEADOCK, E. J. MILLER, E. L. KEUFFEL, M. G. DUNN. Effect of physical crosslinking methods on collagen-fiber durability in proteolytic solutions, *J. Biomed. Mater. Res.* 1996, 32, 221–226.
- [141] RAULT, I., V. FREI, D. HERBAGE, N. ABDUL-MALAK, A. HUC a I-LIN LIANG. Evaluation of different chemical methods for cross-linking collagen gel, films and sponges: An in vivo study. *Journal of Materials Science: Materials in Medicine*. 1996, 7(4), 215–221.
- [142] KHOR, Eugene, V. FREI, D. HERBAGE, N. ABDUL-MALAK, A. HUC a I-LIN LIANG. Methods for the treatment of collagenous tissues for bioprostheses: An in vivo study. *Biomaterials*. 1997, 18(2), 95–105.
- [143] L. H. H. Olde DAMINK, P.J., VAN DIJKSTRA, M. J. A. LUYN, P. B. VAN WACHEM, P. NIEUWENHUIS, J. FEIJEN. Glutaraldehyde as a crosslinking agent for collagen-based biomaterials. *Journal of Materials Science: Materials in Medicine*. 1995, 6 (8), 460–472.
- [144] APOSTOLOV, A. A., BONEVA, D., VASSILEVA, E., MARK, J. E. and FAKIROV, S. (2000), Mechanical properties of native and crosslinked gelatins in a bending deformation. *Journal of Applied Polymer Science*. 2000, 76 (14), 2041–2048.
- [145] PAUL, R. Gordon, Allen J. BAILEY, G. ATTENBURROW, N. ABDUL-MALAK, A. HUC a I-LIN LIANG. Chemical Stabilisation of Collagen as a Biomimetic: An in vivo study. *The Scientific World JOURNAL*. 2003, 3(1), 138–155.
- [146] VAN WACHEM, P. B., M. J. A. VAN LUYN, L. H. H. Olde DAMINK, P. J. DIJKSTRA, J. FEIJEN a P. NIEUWENHUIS. Biocompatibility and tissue regenerating capacity of crosslinked dermal sheep collagen: An in vivo study. *Journal of Biomedical Materials Research*. 1994, 28(3), 353–363.
- [147] OSBORNE, C. S., J. C. VAN LUYN, D. SMITH, M. DIJKSTRA, M. H. GRANT a P. NIEUWENHUIS. Investigation into the tensile properties of collagen/chondroitin-6-sulphate gels: the effect of crosslinking agents and diamines. *Medical*. 1998, 36(1), 129–134.
- [148] M. E. NIMNI, D. CHEUNG, B. STRATES, M. KODAMA, K. SHEIKH. Bioprosthesis derived from crosslinked and chemically modified collagenous tissue. in: M.E. Nimni (Ed.), *Collagen Vol. III – Biotechnology*, CRC Press, Boca Raton, FL, 1988, 1–38.
- [149] S. D. GORHAM. Collagen, in: D. Byrom (Ed.), *Biomaterials*, Stockton Press, New York, 1991, 55–122.
- [150] L. H. H. Olde DAMINK, P. J. DIJKSTRA, M. J. A. van LUYN, P. B. van WACHEM, P. NIEUWENHUIS, J. FEIJEN. In vitro degradation of dermal sheep

- collagen crosslinked using a water-soluble carbodiimide, *Biomaterials*. 1996, 17, 679–684.
- [151] CHARULATHA V., RAJARAM A.. Influence of different crosslinking treatments on the physical properties of collagen membranes. *Biomaterials*. 2003, 24, 759–67.
- [152] LEE J. M., EDWARDS H. H. O.L, PEREIRA C. A., SAMII S. I.. Crosslinking of tissue-derived biomaterials in 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC). *J Mater Sci: Mater Med*. 1996, 7, 531–41.
- [153] SPEER, Donald P., Milos CHVAPIL, C. D. ESKELSON, Judith ULREICH a K. RUBINI. Biological effects of residual glutaraldehyde in glutaraldehyde-tanned collagen biomaterials. *Journal of Biomedical Materials Research*. 1980, 14(6), 753–764.
- [154] HE, Lirong, Changdao MU, Jiabo SHI, Qian ZHANG, Bi SHI a Wei LIN. Modification of collagen with a natural cross-linker, procyanidin. *International Journal of Biological Macromolecules*. 2011,48(2), 354–359.
- [155] P. NIEUWENHUIS. Cross-linking of extruded collagen fibers—A biomimetic three-dimensional scaffold for tissue engineering applications: the effect of crosslinking agents and diamines. *Journal of Biomedical Materials Research Part A*. 2009, **89A**(4), 895–908.
- [156] ZEUGOLIS, Dimitrios I., Gordon R. PAUL, Geoffrey ATTENBURROW, M. SAVAKIS, M. H. GRANT a P. NIEUWENHUIS. Cross-linking of extruded collagen fibers—A biomimetic three-dimensional scaffold for tissue engineering applications: the effect of crosslinking agents and diamines. *Journal of Biomedical Materials Research Part A*. 2009, **89A**(4), 895–908.
- [157] KOOB, Thomas J., Daniel J. HERNANDEZ, Geoffrey ATTENBURROW, M. SAVAKIS, M. H. GRANT a P. NIEUWENHUIS. Material properties of polymerized NDGA–collagen composite fibers: development of biologically based tendon constructs. *Biomaterials*. 2002, **23**(1), 203–212.
- [158] LIAO, Xue pin, Zhong bing LU, Bi SHI, M. SAVAKIS, M. H. GRANT a P. NIEUWENHUIS. Selective Adsorption of Vegetable Tannins onto Collagen Fibers: development of biologically based tendon constructs. *Industrial*. 2003, **42**(14), 3397–3402.
- [159] CHANG, Yen, Cheng-Kuo HSU, Hao-Ji WEI, Sung-Ching CHEN, Huang-Chien LIANG, Po-Hong LAI a Hsing-Wen SUNG. Cell-free xenogenic vascular grafts fixed with glutaraldehyde or genipin: In vitro and in vivo studies. *Journal of Biotechnology*. 2005, **120**(2), 207–219.
- [160] NAIDU, M., C.-Y.K. KUAN, W.-L. LO, M. RAZA, A. TOLKOVSKY, N.-K. MAK, R.N.-S. WONG a R. KEYNES. Analysis of the action of euxanthone, a plant-derived compound that stimulates neurite outgrowth: In vitro and in vivo studies. *Neuroscience*. 2007, **148**(4), 915–924.
- [161] CHEN, Yueh-Sheng, Ju-Ying CHANG, Chun-Yuan CHENG, Fuu-Jen TSAI, Chun-Hsu YAO, Bai-Shuan LIU, R.N.-S. WONG a R. KEYNES. An in vivo evaluation of a biodegradable genipin-cross-linked gelatin peripheral nerve guide conduit material: In vitro and in vivo studies. *Biomaterials*. 2005, **26**(18), 3911–3918.
- [162] KOOB, Thomas J, Ju-Ying CHANG, Chun-Yuan CHENG, Fuu-Jen TSAI, Chun-Hsu YAO, Bai-Shuan LIU, R.N.-S. WONG a R. KEYNES. Biomimetic approaches to tendon repair: In vitro and in vivo studies. *Comparative Biochemistry and Physiology Part A: Molecular*. 2002, **133**(4), 1171–1192.

- [163] KITANO, Ai, Shizuya SAIKA, Osamu YAMANAKA, et al. Genipin Suppresses Subconjunctival Fibroblast Migration, Proliferation and Myofibroblast Transdifferentiation: In vitro and in vivo studies. *Ophthalmic Research*. 2006, **38**(6), 355–360.
- [164] BIGI, A., G. COJAZZI, S. PANZAVOLTA, N. ROVERI a K. RUBINI. Stabilization of gelatin films by crosslinking with genipin. *Biomaterials*. 2002, 23(24), 4827–4832.
- [165] ZHAO, Xuan, Yang LIU, Weichang LI, Kai LONG, Lin WANG, Sa LIU, Yingjun WANG a Li REN. Collagen based film with well epithelial and stromal regeneration as corneal repair materials: Improving mechanical property by crosslinking with citric acid. *Materials Science and Engineering: C*. 2015, 55: 201–208.
- [166] ZEUGOLIS, D.I., R.G. PAUL, G. ATTENBURROW, N. ABDUL-MALAK, A. HUC a I-LIN LIANG. The influence of a natural cross-linking agent (*Myrica rubra*) on the properties of extruded collagen fibres for tissue engineering applications: An in vivo study. *Materials Science and Engineering: C*. 2010, 30(1), 190–195.
- [167] HE, Lirong, Changdao MU, Jiabo SHI, Qian ZHANG, Bi SHI a Wei LIN. Modification of collagen with a natural cross-linker, procyanidin. *International Journal of Biological Macromolecules*. 2011, 48(2), 354–359.
- [168] CHUNG, Sangwon, Nilesh P. INGLE, Gerardo A. MONTERO, Soo Hyun KIM, Martin W. KING, Dieter ZUR NEDDEN a Francis H. TOMLINSON. Bioresorbable elastomeric vascular tissue engineering scaffolds via melt spinning and electrospinning: 1988 to 1997. *Acta Biomaterialia*. 2010, **6**(6), 1958–1967.
- [169] LAO, Lihong, Yingjun WANG, Yang ZHU, Yuying ZHANG, Changyou GAO, Dieter ZUR NEDDEN a Francis H. TOMLINSON. Poly(lactide-co-glycolide)/hydroxyapatite nanofibrous scaffolds fabricated by electrospinning for bone tissue engineering: 1988 to 1997. *Journal of Materials Science: Materials in Medicine*. 2011, **22**(8), 1873–1884.
- [170] SOLIMAN, Sherif, Stefania PAGLIARI, Antonio RINALDI, et al. Multiscale three-dimensional scaffolds for soft tissue engineering via multimodal electrospinning: 1988 to 1997. *Acta Biomaterialia*. 2010, **6**(4), 1227–1237.
- [171] BLAKER, Jonny J., Jonathan C. KNOWLES, Richard M. DAY, et al. Novel fabrication techniques to produce microspheres by thermally induced phase separation for tissue engineering and drug delivery: 1988 to 1997. *Acta Biomaterialia*. 2008, **4**(2), 264–272.
- [172] BUDYANTO, L., Y. Q. GOH, C. P. OOI, et al. Fabrication of porous poly(L-lactide) (PLLA) scaffolds for tissue engineering using liquid–liquid phase separation and freeze extraction: 1988 to 1997. *Journal of Materials Science: Materials in Medicine*. 2009, **20**(1), 105–111.
- [173] HEIJKANTS, R. G. J. C., T. G. VAN TIENEN, J. H. DE GROOT, et al. Preparation of a polyurethane scaffold for tissue engineering made by a combination of salt leaching and freeze-drying of dioxane: 1988 to 1997. *Journal of Materials Science*. 2006, **41**(8), 2423–2428.
- [174] SULTANA, Naznin, Min WANG, J. H. DE GROOT, et al. PHBV/PLLA-based composite scaffolds fabricated using an emulsion freezing/freeze-drying technique for bone tissue engineering: surface modification and in vitro biological evaluation. *Biofabrication*. 2012, **4**(1), –.
- [175] NAGAHAMA, Koji, Tatsuro OUCHI, Yuichi OHYA, et al. Temperature-Induced Hydrogels Through Self-Assembly of Cholesterol-Substituted Star PEG- b -PLLA

- Copolymers: An Injectable Scaffold for Tissue Engineering. *Advanced Functional Materials*. 2008, **18**(8), 1220–1231.
- [176] PECK, Marissa, Nathalie DUSSERRE, Todd N. MCALLISTER, et al. Tissue engineering by self-assembly: An Injectable Scaffold for Tissue Engineering. *Materials Today*. 2011, **14**(5), 218–224.
- [177] WEI, Guobao, Peter X. MA, Todd N. MCALLISTER, et al. Nanostructured Biomaterials for Regeneration: An Injectable Scaffold for Tissue Engineering. *Advanced Functional Materials*. 2008, **18**(22), 3568–3582.
- [178] GROEBER, Florian, Monika HOLEITER, Martina HAMPEL, et al. Skin tissue engineering — In vivo and in vitro applications: An Injectable Scaffold for Tissue Engineering. *Advanced Drug Delivery Reviews*. 2011, **63**(4–5), 352–366.
- [179] KOROSSIS, Sotirios, Fiona BOLLAND, Jenny SOUTHGATE, et al. Regional biomechanical and histological characterisation of the passive porcine urinary bladder: Implications for augmentation and tissue engineering strategies. *Biomaterials*. 2009, **30**(2), 266–275.
- [180] WIMPENNY, I., N. ASHAMMAKHI, Y. YANG, et al. Chondrogenic potential of electrospun nanofibres for cartilage tissue engineering: Implications for augmentation and tissue engineering strategies. *Journal of Tissue Engineering and Regenerative Medicine*. 2012, **6**(7), 536–549.
- [181] HUANG, Guo You, Li Hong ZHOU, Qian Cheng ZHANG, et al. Microfluidic hydrogels for tissue engineering: Implications for augmentation and tissue engineering strategies. *Biofabrication*. 2011, **3**(1), –.
- [182] NICHOL, Jason W., Ali KHADEMHOSEINI, Qian Cheng ZHANG, et al. Modular tissue engineering: engineering biological tissues from the bottom up. *Soft Matter*. 2009, **5**(7), 1312–.
- [183] NAPOLITANO, Anthony P., Peter CHAI, Dylan M. DEAN, et al. Dynamics of the Self-Assembly of Complex Cellular Aggregates on Micromolded Nonadhesive Hydrogels: engineering biological tissues from the bottom up. *Tissue Engineering*. 2007, **13**(8), 2087–2094.
- [184] YAMATO, Masayuki, Teruo OKANO, Dylan M. DEAN, et al. Cell sheet engineering: engineering biological tissues from the bottom up. *Materials Today*. 2004, **7**(5), 42–47.
- [185] TAVANA, Hossein, Bobale MOSADEGH, Shuichi TAKAYAMA, et al. Polymeric Aqueous Biphasic Systems for Non-Contact Cell Printing on Cells: Engineering Heterocellular Embryonic Stem Cell Niches. *Advanced Materials*. 2010, **22**(24), 2628–2631.
- [186] DU, Y., E. LO, S. ALI, et al. Directed assembly of cell-laden microgels for fabrication of 3D tissue constructs: Engineering Heterocellular Embryonic Stem Cell Niches. *Proceedings of the National Academy of Sciences*. 2008, **105**(28), 9522–9527.
- [187] KHADEMHOSEINI, Ali, Robert LANGER, S. ALI, et al. Microengineered hydrogels for tissue engineering: Engineering Heterocellular Embryonic Stem Cell Niches. *Biomaterials*. 2007, **28**(34), 5087–5092.
- [188] LU, Tingli, Yuhui LI, Tao CHEN, et al. Techniques for fabrication and construction of three-dimensional scaffolds for tissue engineering: Engineering Heterocellular Embryonic Stem Cell Niches. *International Journal of Nanomedicine*. 2007, **28**(34), 337.

- [189] BRAUKER, James H., Victoria E. CARR-BRENDEL, Laura A. MARTINSON, Joanne CRUDELE, William D. JOHNSTON, Robert C. JOHNSON, Zhengang CHA a Changren ZHOU. Neovascularization of synthetic membranes directed by membrane microarchitecture: influence of substrate, pH and medium on the formation of supramolecular assemblies. *Journal of Biomedical Materials Research*. 1995, **29**(12), 1517–1524.
- [190] WANG, N., BUTLER J.P., INGBER D.E. Mechanotransduction across the cell surface and through the cytoskeleton. *Science* [online]. Washington: The American Association for the Advancement of Science, 1993, **260**(5111), 1124 [cit. 2016-02-17].
- [191] LO, H., M.S. PONTICIELLO, K.W. LEONG, Joanne CRUDELE, William D. JOHNSTON, Robert C. JOHNSON, Zhengang CHA a Changren ZHOU. Fabrication of Controlled Release Biodegradable Foams by Phase Separation: influence of substrate, pH and medium on the formation of supramolecular assemblies. *Tissue Engineering*. 1995, **1**(1), 15–28.
- [192] MA, P. X., R. ZHANG. Synthetic nano-scale fibrous extracellular matrix. *Journal of biomedical materials research* [online]. 1990, **46**(1), 60 [cit. 2016-02-17].
- [193] MIKOS, Antonios G., Georgios SARAkinOS, Susan M. LEITE, Joseph P. VACANT, Robert LANGER, Robert C. JOHNSON, Zhengang CHA a Changren ZHOU. Laminated three-dimensional biodegradable foams for use in tissue engineering: influence of substrate, pH and medium on the formation of supramolecular assemblies. *Biomaterials*. 1993, **14**(5), 323–330.
- [194] MOONEY, David J., Linda CIMA, Robert LANGER, Lynt JOHNSON, Linda K. HANSEN, Donald E. INGBER, Joseph P. VACANT a Changren ZHOU. Principles of Tissue Engineering and Reconstruction Using Polymer-Cell Constructs: influence of substrate, pH and medium on the formation of supramolecular assemblies. *MRS Proceedings*. 1991, **252**(5), –.
- [195] HOLY, Chantal E., Molly S. SHOICHET a John E. DAVIES. Engineering three-dimensional bone tissue in vitro using biodegradable scaffolds: Investigating initial cell-seeding density and culture period. *Journal of Biomedical Materials Research* [online]. New York: John Wiley, 2000, **51**(3), 376–382 [cit. 2016-02-17].
- [196] MIKOS, Antonios G, Amy J THORSEN, Lisa A CZERWONKA, Yuan BAO, Robert LANGER, Douglas N WINSLOW, Joseph P VACANTI a Changren ZHOU. Preparation and characterization of poly(l-lactic acid) foams: influence of substrate, pH and medium on the formation of supramolecular assemblies. *Polymer*. 1994, **35**(5), 1068–1077.
- [197] MIKOS A. G., SARAkinOS G., VACANTI J. P., LANGER R. S., CIMA L. G. Biocompatible polymer membranes and methods of preparation of three-dimensional membrane structures. US Patent No. 5,514,378, 1996.
- [198] THOMSON, Robert C., Michael J. YASZEMSKI, John M. POWERS a Antonios G. MIKOS. Fabrication of biodegradable polymer scaffolds to engineer trabecular bone. *Journal of Biomaterials Science, Polymer Edition*. 1996, **7**(1), 23–38.
- [199] BALDWIN, Daniel F., Minuro SHIMBO, Nam P. SUH a Antonios G. MIKOS. The Role of Gas Dissolution and Induced Crystallization During Microcellular Polymer Processing: A Study of Poly (Ethylene Terephthalate) and Carbon Dioxide Systems. *Journal of Engineering Materials and Technology*. 1995, **117**(1), 62.
- [200] MOONEY, David J., Daniel F. BALDWIN, Nam P. SUH, Joseph P. VACANTI a Robert LANGER. Novel approach to fabricate porous sponges of poly(d,l-lactic-

- co-glycolic acid) without the use of organic solvents: A Study of Poly (Ethylene Terephthalate) and Carbon Dioxide Systems. *Biomaterials*. 1996, **17**(14), 1417–1422.
- [201] SHASTRI, Venkatram Prasad, Ivan MARTIN a Robert LANGER. Macroporous Polymer Foams by Hydrocarbon Templating. *Proceedings of the National Academy of Sciences of the United States of America* [online]. National Academy of Sciences of the United States of America, 2000, **97**(5), 1970–1975 [cit. 2016-02-17].
- [202] WHANG. K.. C.H. THOMAS. K.E. HEALY. G. NUBER a Robert LANGER. A novel method to fabricate bioabsorbable scaffolds: A Study of Poly (Ethylene Terephthalate) and Carbon Dioxide Systems. *Polymer*. 1995. **36**(4). 837–842.
- [203] HEALY K. E., WHANG K., THOMAS C. H. Method of fabricating emulsion freeze-dried scaffold bodies and resulting products. US Patent No. 5,723,508, 1998.
- [204] HARRIS, L D, B S KIM a D J MOONEY. Open pore biodegradable matrices formed with gas foaming. *Journal of biomedical materials research* [online]. 1998, **42**(3), 396 [cit. 2016-02-17].
- [205] LEONG, K.F., C.M. CHEAH a C.K. CHUA. Solid freeform fabrication of three-dimensional scaffolds for engineering replacement tissues and organs. *Biomaterials*. 2003, **24**(13): 2363–2378.
- [206] CHEE KAI, Chua a Leong KAH FAI. Rapid prototyping in Singapore: 1988 to 1997. *Rapid Prototyping Journal*. 1997, **3**(3), 116–119.
- [207] KRUTH, J.P. a Leong KAH FAI. Material Incess Manufacturing by Rapid Prototyping Techniques: 1988 to 1997. *CIRP Annals – Manufacturing Technology*. 1991, **40**(2), 603–614.
- [208] D'URSO, Paul S., David J. EFFENEY, W. John EARWAKER, Timothy M. BARKER, Michael J. REDMOND, Robert G. THOMPSON a Francis H. TOMLINSON. Custom cranioplasty using stereolithography and acrylic: 1988 to 1997. *British Journal of Plastic Surgery*. 2000, **53**(3), 200–204.
- [209] SANGHERA, Bal, Satyajit NAIQUE, Yannis PAPA HARILAOU, Andrew AMIS, Michael J. REDMOND, Robert G. THOMPSON a Francis H. TOMLINSON. Preliminary study of rapid prototype medical models: 1988 to 1997. *Rapid Prototyping Journal*. 2001, **7**(5), 275–284.
- [210] LEONG, K. F., K. K. S. PHUA, C. K. CHUA, Z. H. DU, K. O. M. TEO, Robert G. THOMPSON a Francis H. TOMLINSON. Fabrication of porous polymeric matrix drug delivery devices using the selective laser sintering technique: 1988 to 1997. *Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine*. 2001, **215**(2), 191–192.
- [211] RECHEIS, Wolfgang, Gerhard W WEBER, Katrin SCHÄFER, Rudolf KNAPP, Horst SEIDLER, Dieter ZUR NEDDEN a Francis H. TOMLINSON. Virtual reality and anthropology: 1988 to 1997. *European Journal of Radiology*. 1999, **31**(2), 88–96.
- [212] ZOLLIKOFER, C.P.E., M.S. PONCE DE LEON, Katrin SCHÄFER, Rudolf KNAPP, Horst SEIDLER, Dieter ZUR NEDDEN a Francis H. TOMLINSON. Tools for rapid prototyping in the biosciences: 1988 to 1997. *IEEE Computer Graphics and Applications*. 1999, **15**(6), 48–55.
- [213] VANEZIS, P., M. VANEZIS, G. MCCOMBE, T. NIBLETT, Horst SEIDLER, Dieter ZUR NEDDEN a Francis H. TOMLINSON. Facial reconstruction using 3-D

- computer graphics: 1988 to 1997. *Forensic Science International*. 2000, 108(2), 81–95.
- [214] SACHLOS, E., J. T. CZERNUSZKA. Making tissue engineering scaffolds work. Review: the application of solid freeform fabrication technology to the production of tissue engineering scaffolds. *European cells & materials* [online]. 2003, 5, 29–3940 [cit. 2015-11-04].
- [215] SMITH, L.A., P.X. MA, Clemens A VAN BLITTERSWIJK, et al. Nano-fibrous scaffolds for tissue engineering: Engineering Heterocellular Embryonic Stem Cell Niches. *Colloids and Surfaces B: Biointerfaces*. 2004, **39**(3), 125–131.
- [216] KUNTZ, R.M., W.M. SALTZMAN, Clemens A VAN BLITTERSWIJK, et al. Neutrophil motility in extracellular matrix gels: mesh size and adhesion affect speed of migration. *Biophysical Journal*. 1997, **72**(3), 1472–1480.
- [217] WANG, Xianfeng, Bin DING a Bingyun LI. Biomimetic electrospun nanofibrous structures for tissue engineering. *Materials Today*. 2013, 16(6), 229–241.
- [218] NOLSØE, Helgi, Sinan IMER a Herbert O. HULTIN. Study of how phase separation by filtration instead of centrifugation affects protein yield and gel quality during an alkaline solubilisation process – different surimi-processing methods. *International Journal of Food Science*. 2007, **42**(2), 139–147.
- [219] AUTISSIER, Aude, Catherine Le VISAGE, Cécile POUZET, Frédéric CHAUBET, Didier LETOURNEUR, Yunfeng SHI, Zhengang CHA a Changren ZHOU. Fabrication of porous polysaccharide-based scaffolds using a combined freeze-drying/cross-linking process: influence of substrate, pH and medium on the formation of supramolecular assemblies. *Acta Biomaterialia*. 2010, 6(9), 3640–3648.
- [220] GUILLEN, Gregory R., Yinjin PAN, Minghua LI a Eric M. V. HOEK. Preparation and Characterization of Membranes Formed by Nonsolvent Induced Phase Separation: A Review. *Industrial*. 2011, **50**(7), 3798–3817.
- [221] NAM, Yoon Sung, Tae Gwan PARK, Minghua LI a Eric M. V. HOEK. Biodegradable polymeric microcellular foams by modified thermally induced phase separation method: A Review. *Biomaterials*. 1999, **20**(19), 1783–1790.
- [222] SHAO, Jundong, Cong CHEN, Yingjun WANG, Xiaofeng CHEN a Chang DU. Early stage structural evolution of PLLA porous scaffolds in thermally induced phase separation process and the corresponding biodegradability and biological property: A Review. *Polymer Degradation and Stability*. 2012, **97**(6), 955–963.
- [223] PISANO, Roberto, Antonello A. BARRESI, Davide FISSORE, Frédéric CHAUBET, Didier LETOURNEUR, Yunfeng SHI, Zhengang CHA a Changren ZHOU. Innovation in Monitoring Food Freeze Drying: influence of substrate, pH and medium on the formation of supramolecular assemblies. *Drying Technology*. 2011, 29(16), 1920–1931.
- [224] GANGULY, Arnab, Steven L. NAIL, Alina A. ALEXEENKO, Uma Maheswari KRISHNAN, Rong ZENG, Yunfeng SHI, Zhengang CHA a Changren ZHOU. Rarefied gas dynamics aspects of pharmaceutical freeze-drying: influence of substrate, pH and medium on the formation of supramolecular assemblies. *Vacuum*. 2012, 86(11), 1739–1747.
- [225] LIU, Huihua, Kyuya NAKAGAWA, Dai-ichiro KATO, Deeptangshu CHAUDHARY, Moses O. TADÉ, Yunfeng SHI, Zhengang CHA a Changren ZHOU. Enzyme encapsulation in freeze-dried bionanocomposites prepared from chitosan and xanthan gum blend: influence of substrate, pH and medium

- on the formation of supramolecular assemblies. *Materials Chemistry and Physics*. 2011, 129(1–2), 488–494.
- [226] LIU, Huinan a Thomas J. WEBSTER. Bioinspired Nanocomposites for Orthopedic Applications. *Nanotechnology for the Regeneration of Hard and Soft Tissues*. WORLD SCIENTIFIC, 2007, 1, –.
- [227] MA, Peter X, Cong CHEN, Yingjun WANG, Xiaofeng CHEN a Chang DU. Scaffolds for tissue fabrication: A Review. *Materials Today*. 2004, 7(5), 30–40.
- [228] MA, P. X., R. ZHANG, G. XIAO, R. FRANCESCHI. Engineering new bone tissue in vitro on highly porous poly(alpha-hydroxyl acids)/hydroxyapatite composite scaffolds. *Journal of biomedical materials research* [online]. 0010n. 1., 54(2), 284 [cit. 2016-02-17].
- [229] ZHAO, Jianhao, Wanqing HAN, Haodong CHEN, Mei TU, Rong ZENG, Yunfeng SHI, Zhengang CHA a Changren ZHOU. Preparation, structure and crystallinity of chitosan nano-fibers by a solid–liquid phase separation technique: A Review. *Carbohydrate Polymers*. 2011, 83(4), 1541–1546.
- [230] MA, Peter X., Seongbong JO, Antonios G. MIKOS, Mei TU, Rong ZENG, Yunfeng SHI, Zhengang CHA a Changren ZHOU. Biomimetic materials for tissue engineering: A Review. *Advanced Drug Delivery Reviews*. 2008, 60(2), 184–198.
- [231] CEN, Lian, Wei LIU, Lei CUI, Wenjie ZHANG a Yilin CAO. Collagen Tissue Engineering: Development of Novel Biomaterials and Applications. *Pediatric Research*. 2008, 63(5), 492–496.
- [232] MEIMANDI-PARIZI, Abdolhamid, Ahmad ORYAN, Ali MOSHIRI, Wenjie ZHANG a Yilin CAO. Role of tissue engineered collagen based tridimensional implant on the healing response of the experimentally induced large Achilles tendon defect model in rabbits: a long term study with high clinical relevance. *Journal of Biomedical Science*. 2013, 20(1), 28–.
- [233] SELL, Scott A., Patricia S. WOLFE, Koyal GARG, Jennifer M. MCCOOL, Isaac A. RODRIGUEZ a Gary L. BOWLIN. The Use of Natural Polymers in Tissue Engineering: A Focus on Electrospun Extracellular Matrix Analogues. *Polymers*. 2010, 2(4), 522–553.
- [234] ZANDER, Nicole. Hierarchically Structured Electrospun Fibers. *Polymers*. 2013, 5(1), 19–44.
- [235] SHARMA, Jaishri, Monira LIZU, Mark STEWART, et al. Multifunctional Nanofibers towards Active Biomedical Therapeutics: A Focus on Electrospun Extracellular Matrix Analogues. *Polymers*. 2015, 7(2), 186–219.
- [236] ZUBER, Mohammad, Fatima ZIA, Khalid Mahmood ZIA, et al. Collagen based polyurethanes—A review of recent advances and perspective: A Focus on Electrospun Extracellular Matrix Analogues. *International Journal of Biological Macromolecules*. 2015, 80(2), 366–374.
- [237] MATTHEWS, J. A., G.E. WNEK, D. G. SIMPSON a G. L. BOWLIN. Electrospinning of collagen nanofibers. *Biomacromolecules*. 2002, (3): 232–8.
- [238] OFFEDDU, Giovanni S., Jennifer C. ASHWORTH, Ruth E. CAMERON, et al. Multi-scale mechanical response of freeze-dried collagen scaffolds for tissue engineering applications: A Focus on Electrospun Extracellular Matrix Analogues. *Journal of the Mechanical Behavior of Biomedical Materials*. 2015, 42(2), 19–25.

- [239] DONG, Chanjuan, Yonggang LV, Christina KWON, et al. Application of Collagen Scaffold in Tissue Engineering: Recent Advances and New Perspectives. *Polymers*. 2016, **8**(2), 42–.
- [240] GORDON, Marion K., Rita A. HAHN, Ruth E. CAMERON, et al. Collagens: A Focus on Electrospun Extracellular Matrix Analogues. *Cell and Tissue Research*. 2010, **339**(1), 247–257.
- [241] MIYAZAKI, Toshiki, Kunio ISHIKAWA, Yuki SHIROSAKI, et al. Organic–Inorganic Composites Designed for Biomedical Applications: A Focus on Electrospun Extracellular Matrix Analogues. *Biological and Pharmaceutical Bulletin*. 2013, **36**(11), 1670–1675.
- [242] MIYAZAKI, T., A. SUGAWARA-NATURAKI, C. OHTSUKI. Organic–Inorganic Composites Toward Biomedical Applications. *Biomaterials for Oral and Craniomaxillofacial Applications*. 2015, **17**(11), 33–38.
- [243] HAJIMIRI, Mirhamed, Sheida SHAHVERDI, Golnaz KAMALINIA, et al. Growth factor conjugation: Strategies and applications. *Journal of Biomedical Materials Research Part A*. 2015, **103**(2), 819–838.
- [244] CHAMBERLAIN, L.J., I.V. YANNAS, H-P. HSU, et al. Collagen-GAG Substrate Enhances the Quality of Nerve Regeneration through Collagen Tubes up to Level of Autograft: A Comparative In Vivo Confocal Microscopy Study. *Experimental Neurology*. 1998, **154**(2), 315–329.
- [245] ARCHIBALD, Simon J., Christian KRARUP, Jeremy SHEFNER, et al. A collagen-based nerve guide conduit for peripheral nerve repair: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. *The Journal of Comparative Neurology*. 1991, **306**(4), 685–696.
- [246] COLIN, W., R.B. DONOFF, Jeremy SHEFNER, et al. Nerve Regeneration Through Collagen Tubes: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. *Journal of Dental Research*. 1984, **63**(7), 987–993.
- [247] HUDSON, Terry W., Scott ZAWKO, Curt DEISTER, et al. Optimized Acellular Nerve Graft Is Immunologically Tolerated and Supports Regeneration: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. *Tissue Engineering*. 2004, **10**(11–12), 1641–1651.
- [248] MADAGHIELE, Marta, Alessandro SANNINO, Ioannis V. YANNAS, et al. Collagen-based matrices with axially oriented pores: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. *Journal of Biomedical Materials Research Part A*. 2008, **85A**(3), 757–767.
- [249] BOZKURT, Ahmet, Gary A. BROOK, Sven MOELLERS, et al. In Vitro Assessment of Axonal Growth Using Dorsal Root Ganglia Explants in a Novel Three-Dimensional Collagen Matrix: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. *Tissue Engineering*. 2007, **13**(12), 2971–2979.
- [250] SUN, Wenjie, Hang LIN, Bing CHEN, et al. Collagen scaffolds loaded with collagen-binding NGF- β accelerate ulcer healing: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. *Journal of Biomedical Materials Research Part A*. 2009, **9999A**(12), –.
- [251] SUN, Wenjie, Hang LIN, Bing CHEN, et al. Promotion of peripheral nerve growth by collagen scaffolds loaded with collagen-targeting human nerve growth factor- β : An electrophysiological study of nerve regeneration in rodents and nonhuman

- primates. *Journal of Biomedical Materials Research Part A*. 2007, **83A**(4), 1054–1061.
- [252] MARCHESI, C., M. PLUDERI, F. COLLEONI, et al. Skin-derived stem cells transplanted into resorbable guides provide functional nerve regeneration after sciatic nerve resection: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. *Glia*. 2007, **55**(4), 425–438.
- [253] BOZKURT, Ahmet, Ronald DEUMENS, Christina BECKMANN, et al. In vitro cell alignment obtained with a Schwann cell enriched microstructured nerve guide with longitudinal guidance channels: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. *Biomaterials*. 2009, **30**(2), 169–179.
- [254] KEMP, Stephen W.P., Shahbaz SYED, Sarah K. WALSH, et al. Collagen Nerve Conduits Promote Enhanced Axonal Regeneration, Schwann Cell Association, and Neovascularization Compared to Silicone Conduits: An electrophysiological study of nerve regeneration in rodents and nonhuman primates. *Tissue Engineering Part A*. 2009, **15**(8), 1975–1988.
- [255] LEE, Yee-Shuan, Treana LIVINGSTON ARINZEH, Sandrine LORIMIER a William HORNEBECK. Electrospun Nanofibrous Materials for Neural Tissue Engineering. *Polymers*. 2011, **3**(4), 413–426.
- [256] BLAIS, Mathieu, Myriam GRENIER, François BERTHOD, et al. Improvement of Nerve Regeneration in Tissue-Engineered Skin Enriched with Schwann Cells: Effects of hyaluronic acid and firponectin on wound healing. *Journal of Investigative Dermatology*. 2009, **129**(12), 2895–2900.
- [257] ZHENG, Xianyou, Wei WANG, Shen LIU, et al. Enhancement of chondrogenic differentiation of rabbit mesenchymal stem cells by oriented nanofiber yarn-collagen type I/hyaluronate hybrid. *Materials Science and Engineering: C*. 2016, **58**(4), 1071–1076.
- [258] SHARMA, Jaishri, Monira LIZU, Mark STEWART, et al. Enhancement of chondrogenic differentiation of rabbit mesenchymal stem cells by oriented nanofiber yarn-collagen type I/hyaluronate hybrid. *Polymers*. 2015, **7**(2), 186–219.
- [259] MIENALTOWSKI, Michael J., David E. BIRK, Mark STEWART, et al. Structure, Physiology, and Biochemistry of Collagens. *Polymers*. 2015, **7**(2), 5.
- [260] TEDDER, Mary E., Jun LIAO, Benjamin WEED, et al. Stabilized Collagen Scaffolds for Heart Valve Tissue Engineering. *Tissue Engineering Part A*. 2009, **15**(6), 1257–1268.
- [261] EITAN, Yuval, Udi SARIG, Nitsan DAHAN, et al. Acellular Cardiac Extracellular Matrix as a Scaffold for Tissue Engineering: In Vitro Cell Support, Remodeling, and Biocompatibility. *Tissue Engineering Part C: Methods*. 2010, **16**(4), 671–683.
- [262] YANNAS, I., J. BURKE, D. ORGILL, et al. Wound tissue can utilize a polymeric template to synthesize a functional extension of skin. *Science*. 1982, **215**(4529), 174–176.
- [263] DOILLON, Charles J., Frederick H. SILVER, D. ORGILL, et al. Collagen-based wound dressing: Effects of hyaluronic acid and firponectin on wound healing. *Biomaterials*. 1986, **7**(1), 3–8.
- [264] RÉGNIER, Marcelle, Marie-Jeanne STAQUET, Daniel SCHMITT, et al. Integration of Langerhans Cells into a Pigmented Reconstructed Human Epidermis: Effects of hyaluronic acid and firponectin on wound healing. *Journal of Investigative Dermatology*. 1997, **109**(4), 510–512.

- [265] TREMBLAY, Pierre-Luc, Valerie HUDON, Francois BERTHOD, et al. Inosculation of Tissue-Engineered Capillaries with the Host's Vasculature in a Reconstructed Skin Transplanted on Mice: Effects of hyaluronic acid and firponectin on wound healing. *American Journal of Transplantation*. 2005, **5**(5), 510–512.
- [266] BECHETOILLE, Nicolas, Colette DEZUTTER-DAMBUYANT, Odile DAMOUR, et al. Effects of Solar Ultraviolet Radiation on Engineered Human Skin Equivalent Containing Both Langerhans Cells and Dermal Dendritic Cells: Effects of hyaluronic acid and firponectin on wound healing. *Tissue Engineering*. 2007, **13**(11), 2667–2679.
- [267] TROTTIER, Valérie, Guillaume MARCEAU-FORTIER, Lucie GERMAIN, et al. IFATS Collection: Using Human Adipose-Derived Stem/Stromal Cells for the Production of New Skin Substitutes. *STEM CELLS*. 2008, **26**(10), 2713–2723.
- [268] JEAN, Jessica, Marc LAPOINTE, Jacques SOUCY, et al. Development of an in vitro psoriatic skin model by tissue engineering: Using Human Adipose-Derived Stem/Stromal Cells for the Production of New Skin Substitutes. *Journal of Dermatological Science*. 2009, **53**(1), 19–25.
- [269] CORRIVEAU, Marie-Pier, Inès BOUFAIED, Julie LESSARD, et al. The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach. *The Journal of Pathology*. 2009, **217**(4), 534–542.
- [270] NIE, Chunlei, Daping YANG, Steven F. MORRIS, et al. Local delivery of adipose-derived stem cells via acellular dermal matrix as a scaffold: A new promising strategy to accelerate wound healing. *Medical Hypotheses*. 2009, **72**(6), 679–682.
- [271] ALTMAN, A. M., E. S. CHIU, X. BAI, et al. Human Adipose-Derived Stem Cells Adhere to Acellular Dermal Matrix: A new promising strategy to accelerate wound healing. *Aesthetic Plastic Surgery*. 2008, **32**(4), 698–699.
- [272] ALTMAN, Andrew M., Nadine MATTHIAS, Yasheng YAN, et al. Dermal matrix as a carrier for in vivo delivery of human adipose-derived stem cells: A new promising strategy to accelerate wound healing. *Biomaterials*. 2008, **29**(10), 1431–1442.
- [273] LEVIS, Hannah, Julie T DANIELS, Yasheng YAN, et al. New technologies in limbal epithelial stem cell transplantation: A new promising strategy to accelerate wound healing. *Current Opinion in Biotechnology*. 2009, **20**(5), 593–597.
- [274] SCHWAB, I R. Cultured corneal epithelia for ocular surface disease. *Transactions of the American Ophthalmological Society* [online]. 1999, **97**, 891 [cit. 2016-02-21].
- [275] ZAKARIA, Nadia, Carina KOPPEN, Viggo VAN TENDELOO, et al. Standardized Limbal Epithelial Stem Cell Graft Generation and Transplantation: A new promising strategy to accelerate wound healing. *Tissue Engineering Part C: Methods*. 2010, **16**(5), 921–927.
- [276] SHORTT, Alex J., Genevieve A. SECKER, Richard J. LOMAS, et al. The effect of amniotic membrane preparation method on its ability to serve as a substrate for the ex-vivo expansion of limbal epithelial cells: A new promising strategy to accelerate wound healing. *Biomaterials*. 2009, **30**(6), 1056–1065.
- [277] DRAVIDA, Subhadra, Subhash GADDIPATI, May GRIFFITH, et al. A biomimetic scaffold for culturing limbal stem cells: a promising alternative for clinical

- transplantation. *Journal of Tissue Engineering and Regenerative Medicine*. 2008, **2**(5), 263–271.
- [278] GRUETERICH, Martin, Edgar M. ESPANA, Scheffer C.G. TSENG, et al. Ex vivo expansion of limbal epithelial stem cells: amniotic membrane serving as a stem cell niche. *Survey of Ophthalmology*. 2003, **48**(6), 631–646.
- [279] GRIFFITH, M, W B JACKSON, N LAGALI, et al. Artificial corneas: a regenerative medicine approach. *Eye*. 2009, **23**(10), 1985–1989.
- [280] LIU, Y., M. GRIFFITH, M. A. WATSKY, et al. Properties of Porcine and Recombinant Human Collagen Matrices for Optically Clear Tissue Engineering Applications: a regenerative medicine approach. *Biomacromolecules*. 2006, **7**(6), 1819–1828.
- [281] LAGALI, Neil, May GRIFFITH, Per FAGERHOLM, et al. Innervation of Tissue-Engineered Recombinant Human Collagen-Based Corneal Substitutes: A Comparative In Vivo Confocal Microscopy Study. *Investigative Ophthalmology*. 2008, **49**(9), 3895–.
- [282] CARRIER, Patrick, Alexandre DESCHAMBEAULT, Marie`ve TALBOT, et al. Characterization of Wound Reepithelialization Using a New Human Tissue-Engineered Corneal Wound Healing Model: A Comparative In Vivo Confocal Microscopy Study. *Investigative Ophthalmology*. 2008, **49**(4), 1376–.
- [283] RAFAT, Mehrdad, Takeshi MATSUURA, Fengfu LI, et al. Surface modification of collagen-based artificial cornea for reduced endothelialization: A Comparative In Vivo Confocal Microscopy Study. *Journal of Biomedical Materials Research Part A*. 2009, **88A**(3), 755–768.
- [284] BAUMANN, Leslie, Takeshi MATSUURA, Fengfu LI, et al. Dermal fillers: A Comparative In Vivo Confocal Microscopy Study. *Journal of Cosmetic Dermatology*. 2004, **3**(4), 249–250.
- [285] SHEKARRIZ, Bijan, Jyoti UPADHYAY, Savas DEMIRBILEK, et al. Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. *Urology*. 2000, **55**(1), 123–128.
- [286] MINGIN, Gerald C., Jeffery A. STOCK, Moneer K. HANNA, et al. Gastrocystoplasty: Long-term Complications in 22 Patents. *The Journal of Urology*. 1999, **162**(3), 1122–1125.
- [287] LIU, Yan, Shantaram BHARADWAJ, Sang J. LEE, et al. Optimization of a natural collagen scaffold to aid cell–matrix penetration for urologic tissue engineering: Long-term Complications in 22 Patents. *Biomaterials*. 2009, **30**(23–24), 3865–3873.
- [288] PARSHOTAM KUMAR, Gera, Andrew BARKER, Saeed AHMED, et al. Urinary bladder auto augmentation using INTEGRA® and SURGISIS®: an experimental model. *Pediatric Surgery International*. 2010, **26**(3), 275–280.
- [289] AKBAL, Cem, Sang Don LEE, Subah C. PACKER, et al. Bladder Augmentation With Acellular Dermal Biomatrix in a Diseased Animal Model: an experimental model. *The Journal of Urology*. 2006, **176**(4), 1706–1711.
- [290] FIALA, Richard, Ales VIDLAR, Radek VRTAL, et al. Porcine Small Intestinal Submucosa Graft for Repair of Anterior Urethral Strictures: an experimental model. *European Urology*. 2007, **51**(6), 1702–1708.
- [291] FARAHAT, Yasser A., Abdelhamid M. ELBAHNASY, Osama M. EL-GAMAL, et al. Endoscopic Urethroplasty Using Small Intestinal Submucosal Patch in Cases

- of Recurrent Urethral Stricture: A Preliminary Study. *Journal of Endourology*. 2009, **23**(12), 2001–2005.
- [292] EL KASSABY, AbdelWahab, Tamer ABOUSHWAREB, Anthony ATALA, et al. Randomized Comparative Study Between Buccal Mucosal and Acellular Bladder Matrix Grafts in Complex Anterior Urethral Strictures: A Preliminary Study. *The Journal of Urology*. 2008, **179**(4), 1432–1436.
- [293] BOUHOUT, Sara, Émilie PERRON, Robert GAUVIN, et al. In Vitro Reconstruction of an Autologous, Watertight, and Resistant Vesical Equivalent: A Preliminary Study. *Tissue Engineering Part A*. 2010, **16**(5), 1539–1548.
- [294] ATALA, Anthony, Stuart B BAUER, Shay SOKER, et al. Tissue-engineered autologous bladders for patients needing cystoplasty: A Preliminary Study. *The Lancet*. 2006, **367**(9518), 1241–1246.
- [295] MAGNAN, Martine, François BERTHOD, Marie-France CHAMPIGNY, et al. In vitro reconstruction of a tissue-engineered endothelialized bladder from a single porcine biopsy: A Preliminary Study. *Journal of Pediatric Urology*. 2006, **2**(4), 261–270.
- [296] OBERSON, Christophe, Ariane BOUBAKER, Pascal RAMSEYER, Blaise Julien MEYRAT a Peter FREY. Endoscopic and surgical treatment of vesico-ureteral reflux in children. Comparative long-term follow-up. *Swiss medical weekly* [online]. 2007, **137**(33–34), 471 [cit. 2016-02-21].
- [297] ISOM-BATZ, Ginger, Philippe E. ZIMMERN, Marie-France CHAMPIGNY, et al. Collagen Injection for Female Urinary Incontinence After Urethral or Periurethral Surgery: A Preliminary Study. *The Journal of Urology*. 2009, **181**(2), 701–704.
- [298] KODURI, Sumana, Roger P. GOLDBERG, Christina KWON, et al. Factors influencing the long-term success of periurethral collagen therapy in the office: A Preliminary Study. *International Urogynecology Journal*. 2006, **17**(4), 346–351.
- [299] PUPPI D., CHIELLINI F., PIRAS A. M., CHIELLINI E. Polymeric materials for bone and cartilage repair. *Prog Polym Sci*. 2010, **35**, 403–440.
- [300] BENTKOVER, Stuart, Sheida SHAHVERDI, Golnaz KAMALINIA, et al. The Biology of Facial Fillers: Strategies and applications. *Facial Plastic Surgery*. 2009, **25**(02), 073–085.
- [301] MAO, Jeremy J., Michael S. STOSICH, Eduardo K. MOIOLI, et al. Facial Reconstruction by Biosurgery: Cell Transplantation Versus Cell Homing. *Tissue Engineering Part B: Reviews*. 2010, **16**(2), 257–262.
- [302] GURNEY, Theresa A., David W. KIM, Eduardo K. MOIOLI, et al. Applications of Porcine Dermal Collagen (ENDURAGen) in Facial Plastic Surgery: Cell Transplantation Versus Cell Homing. *Facial Plastic Surgery Clinics of North America*. 2007, **15**(1), 113–121.
- [303] LIYANAGE, S.H., G.S. PUROHIT, J.N.R. FRYE, et al. Anterior abdominal wall reconstruction with a Permacol implant: Cell Transplantation Versus Cell Homing. *Journal of Plastic, Reconstructive*. 2006, **59**(5), 553–555.
- [304] BELLOWS, C. F., W. JIAN, M. K. MCHALE, et al. Blood vessel matrix: a new alternative for abdominal wall reconstruction. *Hernia*. 2008, **12**(4), 351–358.
- [305] ANSALONI, L., F. CATENA, S. GAGLIARDI, et al. Hernia repair with porcine small-intestinal submucosa: a new alternative for abdominal wall reconstruction. *Hernia*. 2007-7-19, **11**(4), 321–326.

- [306] ADHIRAJAN, Natarajan, Natesan SHANMUGASUNDARAM, Seetharaman SHANMUGANATHAN, et al. Collagen-based wound dressing for doxycycline delivery: in-vivo evaluation in an infected excisional wound model in rats. *Journal of Pharmacy and Pharmacology*. 2009, **61**(12), 1617–1623.
- [307] ADHIRAJAN, N., N. SHANMUGASUNDARAM, S. SHANMUGANATHAN, et al. Functionally modified gelatin microspheres impregnated collagen scaffold as novel wound dressing to attenuate the proteases and bacterial growth: in-vivo evaluation in an infected excisional wound model in rats. *European Journal of Pharmaceutical Sciences*. 2009, **36**(2–3), 235–245.
- [308] SRIPRIYA, Ramasamy, Muthusamy Senthil KUMAR, Mohamed Rafiuddin AHMED, et al. Collagen bilayer dressing with ciprofloxacin, an effective system for infected wound healing: in-vivo evaluation in an infected excisional wound model in rats. *Journal of Biomaterials Science, Polymer Edition*. 2007, **18**(3), 335–351.
- [309] SHANMUGASUNDARAM, N., J. SUNDARASEELAN, S. UMA, et al. Design and delivery of silver sulfadiazine from alginate microspheres-impregnated collagen scaffold: in-vivo evaluation in an infected excisional wound model in rats. *Journal of Biomedical Materials Research Part B: Applied Biomaterials*. 2006, **77B**(2), 378–388.
- [310] MULDER, Gerit, Arthur J. TALLIS, V. Tracy MARSHALL, et al. Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): Results of a Phase 1/2 trial. *Wound Repair and Regeneration*. 2009, **17**(6), 772–779.
- [311] GLATTAUER, Veronica, Jacinta F. WHITE, Wei-Bor TSAI, et al. Preparation of resorbable collagen-based beads for direct use in tissue engineering and cell therapy applications: Results of a Phase 1/2 trial. *Journal of Biomedical Materials Research Part A*. 2009, **9999A**(6), –.
- [312] TAKESHITA, Fumitaka, Naomi HOKAIWADO, Kimi HONMA, et al. Local and Systemic Delivery of siRNAs for Oligonucleotides Therapy: Results of a Phase 1/2 trial. *Journal of Biomedical Materials Research Part A*. 2009, **9999A**(6), 1.
- [313] TAKESHITA, Fumitaka, Takahiro OCHIYA, Kimi HONMA, et al. Therapeutic potential of RNA interference against cancer: Results of a Phase 1/2 trial. *Cancer Science*. 2006, **97**(8), 689–696.
- [314] SANO, A, Takahiro OCHIYA, Kimi HONMA, et al. Atelocollagen for protein and gene delivery: Results of a Phase 1/2 trial. *Advanced Drug Delivery Reviews*. 2003, **55**(12), 689–696.
- [315] FREYMAN, T.M., I.V. YANNAS a L.J. GIBSON. Cellular materials as porous scaffolds for tissue engineering. DOI: 10.1016/S0079-6425(00)00018-9. ISBN 10.1016/S0079-6425(00)00018-9. Accessible from URL: <http://linkinghub.elsevier.com/retrieve/pii/S0079642500000189>
- [316] Arthur J. VANDER, James H. SHERMAN, Dorothy S. LUCIANO, Human Physiology: The Mechanisms of Body Function, Fifth Edition, McGraw-Hill Publishing Company, New York, 1990.
- [317] PETIBOIS, Cyril, Gilles GOUSPILLOU, Katia WEHBE, Jean-Paul DELAGE a Gérard DÉLÉRIS. Analysis of type I and IV collagens by FT-IR spectroscopy and imaging for a molecular investigation of skeletal muscle connective tissue. *Analytical and Bioanalytical Chemistry*. 2006, **386**(7–8), 1961–1966.

- [318] TARAVEL, M. N., A. DOMARD, K. WEHBE, J.-P. DELAGE, G. DÉLÉRIS. Collagen and its interaction with chitosan. *Biomaterials*. 1995, 16(11), 865–871.
- [319] MUYONGA, J. H., C. G. B. COLE, K. G. DUODU, J.-P. DELAGE, G. DÉLÉRIS. Fourier transform infrared (FTIR) spectroscopic study of acid soluble collagen and gelatin from skins and bones of young and adult Nile perch (*Lates niloticus*). *Food Chemistry*. 2004, 86(3), 325–332.
- [320] STUART, Barbara H. *Analytical Techniques in the Sciences*. Chichester, UK: John Wiley, 2005. DOI: 10.1002/0470011149. ISBN 9780470854280.
- [321] URIARTE-MONTOYA, Mario Hiram, Joe Luis ARIAS-MOSCOSO, Maribel PLASCENCIA-JATOMEA, Hisila SANTACRUZ-ORTEGA, Ofelia ROUZAUD-SÁNDEZ, Jose Luis CARDENAS-LOPEZ, Enrique MARQUEZ-RIOS a Josafat Marina EZQUERRA-BRAUER. Jumbo squid (*Dosidicus gigas*) mantle collagen: Extraction, characterization, and potential application in the preparation of chitosan–collagen biofilms. *Bioresource Technology*. 2010, 101(11), 4212–4219.
- [322] CUQ, Bernard, Nathalie GONTARD, Jean-Louis CUQ, Stéphane GUILBERT a Gérard DÉLÉRIS. Selected Functional Properties of Fish Myofibrillar Protein-Based Films As Affected by Hydrophilic Plasticizers. *Journal of Agricultural and Food Chemistry*. 1997, 45(3), 622–626.
- [323] ANGELE, Peter, Jochen ABKE, Richard KUJAT, et al. Influence of different collagen species on physico-chemical properties of crosslinked collagen matrices. *Biomaterials* [online]. Elsevier Ltd, 2004, 25(14), 2831–2841 [cit. 2016-05-04].
- [324] XIA, Zhiyong, Xiomara CALDERON-COLON, Morgana TREXLER, Jennifer ELISSEFF a Qiongyu GUO. Thermal denaturation of type I collagen vitrified gels. *Thermochimica Acta*. 2012, 527, 172–179.
- [325] MAHTO, Sanjeev Kumar, Prakash CHANDRA, Seog Woo RHEE. In vitromodels, endpoints and assessment methods for the measurement of cytotoxicity. *Toxicology and Environmental Health Sciences*. 2010, 2(2), 87–93.
- [326] WIEGAND, Cornelia, Uta-Christina HIPLER. Methods for the measurement of cell and tissue compatibility including tissue regeneration processes. *GMS Krankenhaushygiene Interdisziplinär* [online]. German Medical Science GMS Publishing House. 2008, 3(1), ISSN 1863–5245. [cit. 2016-04-18].
- [327] VON RECUM, A. F., T. G. VAN KOOTEN. The influence of micro-topography on cellular response and the implications for silicone implants. *Journal of Biomaterials Science. Polymer Edition*. 1996, 7(2), 181–198.